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2. Zusammenfassung 
Am Anfang des zwanzigsten Jahrhunderts erfolgte der Einsatz von Bakteriophagen zur 
Bekämpfung bakterieller Infektionen, dies wurde jedoch im Zuge der Entdeckung der 
Antibiotika weitestgehend eingestellt. Ein Neubeginn der Phagentherapie erfolgte erst mit 
dem Auftreten von Antibiotika Resistenzen in Bakterien. Phagen kodierte Endolysine 
erwiesen sich in Tiermodell-Studien als effiziente Wirkstoffe gegen Gram-positive 
Krankheitserreger, die aber aufgrund der geringen Löslichkeit nur bedingt einsetzbar waren. 
In dieser Arbeit wurde ein chimeres Endolysin mit verbesserter Löslichkeit und hoher 
Spezifität gegen Staphylococcus aureus (S. aureus) entwickelt. Der Bakteriophage P68 gehört 
zur Familie der Podoviridae und intiziert S. aureus Stämme. Versuche das Endolysin P16 des 
Phagen P68 zu isolieren scheiterten an der geringen Löslichkeit des Proteins. Daher wurde 
das rekombinante P16-17 Endolysin generiert. Das P16-17 Endolysin besteht aus der 
enzymatisch aktiven N-terminalen D-alanyl-glycyl-endopeptidase Domäne (DAGE) des P16 
Endolysins und der C-terminalen Zellwand bindenden Domäne des P17 Hüllproteins des 
Phagen P68. Dieses chimere Endolysin zeigte neben guter Löslichkeit eine antimikrobielle 
Wirkung gegen S. aureus. Weiterhin verstärkte das P16-17 Endolysin die Wirkung des 
Aminoglycosid-Antibiotikums Gentamycin. Dieser synergistische Effekt könnte ausgenutzt 
werden, um die effektive Dosis von Aminoglycosid-Antibiotika zu reduzieren.  
Das bakterielle Ribosom ist ein Hauptangriffspunkt vieler klinisch relevanter Antibiotika und 
es sind eine Vielzahl von verschiedenen Inhibitionsmechanismen am Ribosom bekannt. Die 
intensive Nutzung von Antibiotika führte in den letzten Jahren zum Auftreten immer neuer 
Resistenzen und zu Bakterienstämmen die gegen mehrere Antibiotika (´´Multi-Drug-Resistent 
Stämme’’) resistent sind. Die eingeschränkte Nutzbarkeit von Antibiotika gegen resistente 
Stämme verlangt nach neuen Therapeutika. In der hier durchgeführten Pilotstudie sollte die 
Möglichkeit der Inhibition der Assemblierung des Ribosom als neues Ziel eines 
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Therapeutikums überprüft werden. Das ribosomale Protein S1 ist für die Translation der 
zellulären messenger RNA (mRNA) in Gram-negativen Bakterien essentiell. Die Bindung 
dieses Proteins an das Ribosom erfolgt über das ribosomale Proteine S2. Eine Störung der 
Interaktion der beiden ribosomalen Proteine S1 und S2 könnte somit zu einem Erliegen der 
Proteinsynthese führen und ist damit ein geeignetes Ziel die Proteinsynthese selektiv in 
Bakterien zu unterbinden, da in höheren Organismen kein S1 Homolog  vorkommt. 
 In den hier durchgeführten ``Yeast-two-hybrid Interaktionsstudien’’ der ribosomalen 
Proteine S1 und S2 wurden verschiedene verkürzte Varianten des Protein S1 benutzt. Diese 
Studien zeigten, das die N-terminale Domäne des S1 (S1106) ausreichend für die Interaktion 
mit dem Ribosom ist. In einer Mutationsanalyse konnte weiterhin eine Variante von S1106, 
gefunden werden, die eine stärkere Interaktion mit dem Protein S2 zeigte. 
           Weiterhin konnte durch Anwendung der Yeast-two-hybrid Interaktionsstudien der 
Interaktionsbereich des Proteins S2 mit Protein S1 auf eine Subdomäne (Helix-Turn-Helix 
zwischen Aminosäure 140 und 150) eingegrenzt werden. Diese Interaktion konnte in vitro mit 
isolierten Mutanten Proteinen bestätigt werden. Die ermittelten Details der Interaktion von 
Protein S1 und S2 eröffnet eine Basis für das Design von neuen chemischen Verbindungen, 
die diese Protein-Protein Interaktion verhindern und somit ein selektives Therapeutikum 
gegen Gram-negative Bakterien bietet könnte. 
 
 
 
 
 
 4
3. Summary 
Bacteriophage therapy has been used at the beginning of the 20th century to combat bacterial 
infections. With the discovery of antibiotics, phage therapy was largely abandoned in western 
countries. However, the rise of antibiotic resistant bacteria has created renewed interest in 
phage as antimicrobials.  In addition, bacteriophage endolysins were shown to be effective 
against Gram-positive pathogens in animal models and resistance to phage endolysins has not 
been reported. However, most endolysins from phages of Gram-positive bacteria show a poor 
solubility. In this work, a chimeric endolysin with an improved solubility was created that 
exerted a high specificity against Staphylococcus aureus.  
     Phage P68 belongs to the family of podoviridae and infects several S. aureus strains 
including nosocomial MRSA (``Methicillin resistant S. aureus’’) strains. Attempts to purify 
the P16 endolysin of phage P68 were unsuccessful owing to the insolubility of the protein. 
This limitation was overcome by the construction of a chimeric P68-derived endolysin, P16-
17. P16-17 consists of the inferred N-terminal D-alanyl-glycyl endopeptidase domain 
(DAGE) of P16 and the C-terminal cell wall binding domain of minor coat protein, P17. The 
domain swapping approach and the applied purification procedure resulted in soluble P16-17 
protein, which exhibited antimicrobial activity towards S. aureus. In addition, P16-17 
augmented the antimicrobial efficacy of the antibiotic gentamicin. This synergistic effect 
could be useful to reduce the effective dose of aminoglycoside antibiotics. 
     The ribosome represents a major target for many clinically relevant antibiotics. However, 
the extensive use of antibiotics to treat bacterial infections has lead to drug resistant pathogens. 
Here a pilot study was conducted with the aim to inhibit ribosome assembly. As protein S1 is 
known to be essential for translation in Gram-negative bacteria and ribosomal protein S2 is 
required for binding of S1 to the ribosome, the S1/S2 interaction was studied. A yeast two 
hybrid system was exploited to study the interactions of protein S1 and truncated variants 
 5
thereof with protein S2. A significantly better interaction was noticed with the truncated 
variant of protein S1, S1106, encompassing 106 amino acids from the N-terminal region. A 
mutant variant of S1106, S1106MUT with changes in two amino acid residues interacted stronger 
with protein S2 when compared with the wild type S1106. Both S1106 and S1106MUT were able to 
bind to ribosomes and caused cell death upon over-production. With the aim to define the 
protein S2 domain, contacting S1, the helix-turn-helix motif situated between 104 and 150 
was scrutinized, and was shown to interact with protein S1 as well as with protein S1106. 
These studies provide a basis for the design of compounds which could possibly disrupt S1/S2 
interactions, and thus could act semi-selectively against Gram-negative pathogens.  
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4. Introduction 
4.1. Staphylococcus aureus 
The genus Staphylococcus belongs to the family Micrococcaceae, which appear as grape-like 
clusters when viewed through a microscope. Staphylococcus aureus forms large, round, 
golden-yellow colonies (Fig. 1), often with β-hemolysis when grown on blood agar plates 
(Lowy, 1998).  The golden appearance of the colonies is the etymological root of the 
bacteria’s name: aureus means “golden” in latin. S. aureus falls in the category of facultative 
anaerobes and opportunistic pathogens (Wilkinson, 1997). 
The genome of S. aureus consists of a circular chromosome of approx. 2.8 Mbp. 
Resistance of S. aureus to antibiotics is brought about by genes located either on the 
chromosome or on plasmids (Novick, 1990).  S. aureus can adapt to a wide range of growth 
conditions including growth over a temperature range of 15 to 45 degrees and NaCl 
concentrations as high as 15 percent. S. aureus forms part of the normal flora of humans 
found on nasal passages, skin and mucous membranes.  
                                    
Fig. 1. Electron micrograph of Staphylococcus aureus  
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4.1.1. Cell wall structure and capsule of S. aureus 
Peptidoglycan constitutes 50% of the weight of S. aureus. The peptidoglycan structure of S. 
aureus is comprised of N-acetylglucosamine and N-acetylmuramic acid with β-1, 4 linkages. 
The tetrapeptide chains bound to N-acetylmuramic acid are cross-linked by penta-glycine 
linkages (Fig. 2), which is a unique feature of the S. aureus cell wall (Lowy 1998). In addition, 
accessory compounds such as teichoic acids, teichuronic acids, polyphosphates or 
carbohydrates are attached to the peptidoglycan skeleton. Ribitol teichoic acids are major 
constituents of the staphylococcal cell wall. The poly-ribitol phosphates, bearing a negative 
charge, are covalently attached to the peptidoglycan. Lipoteichoic acids are glycerol 
phosphate polymers linked to a glycolipid terminus anchored in the cytoplasmic membrane 
(Navarre and Schneewind, 1999).  
 
                 
Fig. 2. Cell wall structure of S. aureus. The FemX, FemA and FemB are enzymes involved in 
the formation of the penta-glycine linkages (Schneider et al., 2004). 
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Most of the staphylococci produce microcapsules. Microcapsule formation helps the bacteria 
to evade the immune system of the host and also plays an important role in increasing 
virulence (Lee and Lee, 2006). Among the 11 types of staphylococcal microcapsular 
serotypes that have been identified, type 5 and 8 account for 80% of human infections (Arbeit 
et al., 1984). Most methicillin-resistant S. aureus isolates belong to type 5. The chemical 
composition of four of these antiphagocytic polysaccharide microcapsules, including type 5 
and 8, has been determined. Type 5 and 8 microcapsules are composed of acidic sugar 
moieties (Fox et al., 1998). 
 
4.1.2. Pathogenicity of S. aureus 
Staphylococcus aureus causes a variety of infections ranging from minor skin lesions like 
boils and furunculosis to complicated and life threatening infections like pneumonia, mastitis, 
phlebitis, meningitis, and urinary tract infections. S. aureus also causes deep-seated infections 
such as osteomyelitis and endocarditis. A significant number of hospital acquired infections 
are caused by S. aureus. S. aureus can also cause food poisoning by releasing enterotoxins 
into food, and toxic shock syndrome by the release of superantigens into the blood stream. 
Virulence factors (Fig. 3) produced by S. aureus include (i) surface proteins that promote 
colonization of host tissue, (ii) invasins (eg: kinases, hyaluronidase, leukocidin) that promote 
bacterial spread in tissues, (iii) surface factors (capsule, protein A), which inhibit phagocytic 
engulfment, (iv) membrane damaging toxins (hemolysins, leukotoxin, leukocidin) that lyse 
eukaryotic cells and (v) exotoxins (SEA-G, TSST, ET) which can damage host tissue. 
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Fig. 3. Virulence factors of Staphylococcus aureus 
There are several features in common to most of the surface virulence factors produced by S. 
aureus. These include the presence of a secretory signal sequence at the N-terminus, a 
hydrophobic membrane spanning domain and a C-terminal cell wall anchoring domain. A 
ligand binding domain at the N-terminal of the surface factors allows these surface proteins to 
function as adhesins (Foster and McDevitt, 1994). An example of a surface protein 
functioning as an adhesin is S. aureus surface protein G (SasG). SasG promotes adhesion of S. 
aureus to nasal epithelial cells and thereby contributes to colonization (Roche et al., 2003). 
Moreover, SasG is involved in biofilm formation (Corrigan et al., 2007). 
S. aureus produces a wide range of toxins. The enterotoxins produced by S. aureus are 
known elements in staphylococci associated food poisoning. Staphylococcus aureus strain 
Fukuoka 5 carries two plasmid encoded enterotoxins, SES and SET. (Ono et al., 2008). The 
extracellular toxins, on the other hand contribute to the pathogenicity of the bacteria (Marrack 
and Kappler 1990). One of the best studied extracellular toxins are the cytotoxins, which 
functions in establishing infections by converting the local tissues at the site of infection to a 
suitable environment that is required for growth of S. aureus (Fueyo et al., 2005). There are 
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numerous cytotoxins produced by S. aureus. Among these, the most important and widely 
studied class of cytotoxins are hemolysins and panton-Valentine leukocidin, also known as 
PV-leukocidin. There are four types of hemolysins, α, β, γ and δ (Dinges et al., 2000). The α- 
hemolysin binds to the membrane of susceptible cells, allowing the toxin to cause small pores 
in the cell membrane through which monovalent cations are released. In humans, platelets and 
monocytes are highly sensitive to α-toxin. The cascade of secondary reactions following toxin 
binding causes the release of cytokines that in turn trigger the production of inflammatory 
mediators. These events cause various symptoms of septic shock that occur during severe 
infections caused by S. aureus (Bhakdi and Tranum-Jensen, 1991). 
The S. aureus β-toxin causes damage of membranes rich in sphingomyelin, thus forms 
the family of sphingomyelinase (Glenny and Stevens, 1989). It is highly haemolytic for sheep 
erythrocytes but not for rabbit erythrocytes. The differing susceptibility of erythrocytes to β-
toxin may be due to the differing sphingomyelin contents of erythrocytes (Doery et al, 1965). 
The sphingomyelinase activity of the β-toxin does not cause lysis of the cells but leaves them 
vulnerable to a number of other lytic agents (Thelestam, 1983).  
The γ-toxins are produced by numerous isolates of S. aureus (Lina et al, 1999). In 
contrast to the α and β toxins, γ-toxins are bi-component pore forming toxins (Sugawara et al., 
1997; Finck-Barbançon et al, 1991; Woodin, 1960). Two genes, hlgA and hlgC, code for the S 
component, whereas, hlgB encodes the F component of the γ-toxin. The individual 
components (S or F) of the γ-toxins are non functional (Prévost et al., 1995).  
There exists a synergistic action between the γ-toxin and the Panton-Valentine 
leukocidin (PV). The genes hlgA and hlgC, encoding for the S-component of PV-leukocidin, 
are carried by a prophage and the F-component is contributed by the γ-toxin that is produced 
by S. aureus (Kamio et al, 1993). PV-leukocidin is a leukocytolytic toxin and has been 
epidemiologically associated with severe cutaneous infections (Dinges et al., 2000). 
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The δ-toxin, produced by many isolates of S. aureus is a surface active protein, which gets 
readily associated with hydrophobic membrane structures, and forms ion channels (Colacicco 
et al., 1977; Mellor et al., 1988). The δ-toxin is able to lyse horse and human erythrocytes. 
Moreover, it inhibits binding of epidermal growth factor (EGF) to cell surface receptors and 
also inhibits water absorption in the ileum by activating adenylate cyclase (Kreger et al., 
1971; Kapral, 1985; Umezawa et al, 1980). 
A wide range of virulence factors are secreted by S. aureus. These include the 
superantigen toxins which include the enterotoxins (A to M) and the toxic shock syndrome 
toxin (TSST-1). They are also known as pyrogenic toxin superantigens (Novick et al., 2001). 
The function of TSST-1 include binding to the major histocompatibility complex (MHC II) 
thereby causing extensive T-cell proliferation and cytokine release, eliciting high fever, rash, 
diarrhea, vomitting and renal dysfunction (Marrack and Kapler, 1990). Staphylococci also 
produce various enzymes that are secreted. These include protease, lipase and hyaluronidase. 
These factors may facilitate spread of the infection to neighbouring tissues.     
 
4.1.3. S. aureus resistance to antimicrobial agents 
The acquisition of virulence factors and high level of antibiotic resistance makes S. aureus to 
a leading cause of infections in hospital settings, especially affecting immunocompromised 
patients (Mandell et al., 2001). One of the challenges in the treatment of nosocomial 
infections worldwide is the appearance of methicillin-resistant S. aureus (MRSA). MRSA 
strains carry an effective drug-resistance mechanism that can protect these pathogens against 
all members of the β-lactam family of antibiotics including methicillin, dicloxacillin, nafcillin, 
and oxacillin (Crisóstomo et al., 2001). The target of β-lactam antibiotics are penicillin 
binding proteins (PBP), which are involved in the final step of peptidoglycan synthesis. 
Bacteria have between four and eight PBPs. In contrast to Gram-negative bacteria, which 
produce β-lactamases, most Gram-positive bacteria gain resistance towards β-lactam 
 12
antibiotics by either changing the specificity of their PBPs or by acquiring new PBPs with 
lower affinity for antibiotics (Mouz et al., 1998).  
   There are two types of MRSA strains: community-acquired MRSA (CA-MRSA) and 
healthcare-associated MRSA (HA-MRSA). CA-MRSA differs from HA-MRSA in clinical, 
bacteriological and epidemiological aspects (Amador-Miranda et al., 2008). The CA-MRSA 
strains are different from HA-MRSA with regard to antimicrobial susceptibility, which can be 
attributed to the presence of SCCmec (mobile genetic element carrying antimicrobial 
resistance genes) (Saïd-Salim et al., 2003). CA-MRSA produces certain virulence factors and 
exotoxins like PV-leukocidin. HA-MRSA produces superantigenic exotoxins and 
staphylococcal enterotoxin A (Tristan et al., 2007).  Vancomycin and teicoplanin are the most 
common glycopeptide antibiotics used to treat both CA-MRSA and HA-MRSA infections 
(Schentag et al., 1998). Vancomycin binds to the peptides of peptidoglycan precursors. This 
blocks the formation of glycosidic bonds between the sugar moieties by transglycosidase and 
peptide cross-links by trans-peptidase enzymes, resulting in the formation of a weak 
peptidoglycan, which is unable to withstand the internal osmotic pressure (Watanakunakorn, 
1984). There is also an emergence of vancomycin-resistant Staphylococcus aureus strains 
(VRSA) (Sievert et al., 2008; Conly and Johnston, 2002). The resistance of S. aureus towards 
vancomycin can be attributed to the presence of van genes, which include vanA (codes for D-
Ala-D-Lac ligase), vanH (encodes a dehydrogenase that produces D-lactate from pyruvate) 
and vanX (encodes a d,d-dipeptidase that destroys D-Ala-D-Ala). In addition, vanR and vanS 
encode a signal transduction system that senses vancomycin in the environment and induces 
expression of resistance genes (Woodford, 2001; Naas et al., 2005). 
 
4.2. Bacteriophages 
 The term bacteriophage accounts for viruses that infect bacteria. Bacteriophages consist of an 
outer protein shell enclosing the genetic material. The genetic material may be single stranded 
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RNA, single stranded DNA, double stranded RNA or double stranded DNA. The size of the 
genetic material can vary from 5 to 500 kilo base-pairs, either in linear or circular orientation. 
Bacteriophages are ubiquitous and can be found in all reservoirs populated by bacteria, 
ranging from fresh water to sea water, and psycrophilic to thermophilic environments 
(Wommack and Colwell, 2000).  The circular double stranded DNA phage account for 95% 
of the bacteriophage population. According to the International Committee on Taxonomy of 
Viruses, phage can be classified according to morphology and nucleic acid. The broad 
classification of double stranded tailed phages is shown in Table 1. 
Table1. Classification of bacteriophages (Mc Grath and van Sinderen, 2007). 
Family Morphology 
 
Nucleic acid 
Myoviridae Non-enveloped,      
contractile tail 
Linear dsDNA 
Siphoviridae Non-enveloped,               
long non- contractile tail 
Linear dsDNA 
Podoviridae Non-enveloped,               
short non- contractile tail 
Linear dsDNA 
Tectiviridae Non-enveloped,               
Isometric 
Linear dsDNA 
Corticoviridae Non-enveloped,               
Isometric 
Circular dsDNA 
Lipothrixviridae Enveloped, rod shaped Linear dsDNA 
Plasmaviridae Enveloped, pleomorphic Circular dsDNA 
Rudiviridae Non-enveloped, rod shaped Linear dsDNA 
Fuselloviridae Non-enveloped,             
lemon shaped 
Circular dsDNA 
Inoviridae Non-enveloped, filamentous Circular ssDNA 
Microviridae Non-enveloped, isometric Circular ssDNA 
Leviviridae Non-enveloped, isometric Linear ssRNA 
Cystoviridae Enveloped, spherical Segmented dsRNA 
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4.2.1. Bacteriophage mediated lysis of bacteria 
For most dsDNA phages, the infection cycle culminates in lysis of the host brought about by 
at least two phage-encoded proteins, the endolysin and the holin. Endolysins can cleave 
glycosidic, amide, or peptide bonds of the bacterial peptidoglycan. The holins on the other 
hand are diverse small membrane proteins with two or three trans-membrane domains (Wang 
et al., 2003). In phage λ, the holin and endolysin are encoded by gene S and R, respectively. 
Both of these genes are located at the beginning of the late transcriptional unit. The endolysin 
accumulates in the cytoplasm following the activation of the late transcriptional unit (Young 
et al., 2000). At a ‘genetically determined time’ the holin forms inner membrane lesions 
through which the endolysin can gain access to the peptidoglycan (Young et al., 2000; Young, 
1992). The accumulation of the holin protein has negligible effect on the host bacteria until 
the completion of replication cycle. (Gründling et al., 2001; Wang et al., 2000). The sequence 
of events involved in the formation of membrane lesions by holin is discussed in section 
4.2.1.1.   
All dsDNA phages utilize the holin-lysin system to achieve host cell lysis (Fig. 4) with 
the exeption of a few phages of Gram-negative bacteria, which use the sec system to target the 
endolysin to the periplasm (São-José et al., 2000). The secreted endolysins remain tethered at 
the periplasmic site of the inner membrane in an inactive form by the N-terminal SAR (Signal 
Arrest Release) sequence, that functions as a type II signal anchor (Xu, et al., 2004; Xu, et al., 
2005). Upon depolarization of the membrane by the holin, the N-terminal SAR sequence of 
the endolysin is released, which causes the activation of the endolysin, followed by cell lysis 
(Xu et al., 2005). Phages of the Gram-negative bacteria, P1 and 21 use SAR endolysins to 
evoke host cell lysis. Furthermore, holins are not absolutely essential for cell lysis by SAR-
endolysins. However, they are thought to control the timing of the lytic event, by depolarizing 
the membrane which accelerates the release of the SAR lysozyme from the periplasmic 
membrane (Xu et al., 2004; Park et al., 2006). 
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Fig. 4. Lysis of Gram-negative bacteria by a phage-encoded holin-endolysin system (modified 
from Young et al., 2000). 
  In addition to holins and endolysins, two accessory phage encoded lysis proteins are 
involved in lysis of Gram-negative bacteria in vivo when the outer membrane is stabilized by 
divalent cations, like Mg2+ (Zhang and Young, 1999; Summer et al., 2007). In phage λ, these 
proteins are the gene products of Rz and Rz1. Equivalents of Rz and Rz1 are found in nearly 
all phages of Gram-negative bacteria including phages, T7 and P2 (Summer et al., 2007). The 
Rz/Rz1 equivalent in phage T7 is gp18.5/gp18.7 and lysB/lysC in phage P2. The Rz/Rz1 and 
gp18.5/gp18.7 genes are overlapping in phage λ and T7, whereby the genes Rz1 and gp18.7 
are embedded within Rz and gp18.5, respectively. In contrast, lysB/lysC from phage P2 exist 
in ‘overlapped’ orientation, where about half of the lysC gene extends beyong the lysB stop 
codon (Summer et al., 2007). The Rz, gp18.5 and lysB encode a polypeptide with a predicted 
N-terminal transmembrane domain (TMD), and the Rz1, gp18.7 and lysC genes encode outer 
membrane lipoprotein (Berry et al., 2008; Kedzierska et al., 1996). The interactions of the Rz 
and Rz1 proteins during the lytic cycle of phage λ facilitates the linking of the host inner and 
 
 
 
                                 
Endolysin 
OM-Outer membrane 
IM  - Inner membrane 
LPP- Lipoprotein 
IM
Holin 
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outer membranes, hence lysis in the presence of high concentrations of divalent cations 
(Summer et al., 2007; Berry et al., 2008).  
Cell lysis by ssDNA and ssRNA phages like ФX174, MS2 and Qβ is achieved by the 
interaction of phage encoded proteins with host enzymes. The ФX174 gene product E, 
required for host cell lysis is localized in the cytoplasmic membrane (Maratea et al., 1985). In 
comparision to other phage ФX174 proteins, protein E is made in small amounts and was 
shown to interact with host proteins encoded by genes slyD and MraY. The SlyD protein is a 
peptidyl-prolyl cis-trans isomerase (PPIase), which is involved in accurate folding and 
stability of protein E (Young, 1992; Roof et al., 1994). The MraY translocase I on the other 
hand catalyzes the formation of the first lipid intermediate in peptidoglycan synthesis (Ikeda 
et al., 1991). Phage ФX174 encoded protein E inhibits the MraY catalyzed step in 
peptidoglycan biosynthesis (Bernhardt et al., 2001a). By protein E binding to MraY the 
incorporation of a specific peptidoglycan precursor, diaminopimelate (DAP), is inhibited 
(Zheng et al., 2008; Bernhardt et al., 2001b).  
Similar to phage ФX174 protein E, protein L of RNA phage MS2 is synthesized in very small 
quantities (Coleman et al., 1983; Kastelein et al., 1982). Protein L is a membrane protein 
which seems to be present at membrane adhesion sites of the cell envelope (Walderich et al., 
1988; Walderich and Höltje, 1989). However, the insertion of protein L alone is not sufficient 
for lysis. Moreover, the membrane lesion effected by protein L is unable to release the 28 nm 
MS2 virions. Protein L appears to trigger the lytic transglycosylase and DD-endopeptidase 
proteins, which exert muralytic activity leading to cell lysis and consequently to phage release 
(Walderich et al., 1988; Goessens et al., 1988).   
Unlike phage ФX174 protein E, which specifically inhibits the incorporation of DAP 
into the murein, protein A2 of phage Qβ evokes host cell lysis by inhibiting the MurA 
(Bernhardt et al., 2001b). MurA is a UDP-N-acetylglucosamine enol-pyruvyl transferase, 
which catalyzes the formation of UDP-N-acetylglucosamine enol-pyruvate from UDP-N-
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acetylglucosamine (Nanninga, 1998). Protein A2 inhibits MurA by a tight and direct binding 
to its ‘substrate-binding cleft’ (Bernhardt et al., 2001b). Interestingly, protein A2 is a 
multifunctional capsid protein of phage Qβ. In addition to its role in host cell lysis, protein A2 
also facilitates binding of the phage to the sex pilus of the bacteria during infection (Winter 
and Gold, 1983). When synthesized, protein A2 remains inactive until it becomes assembled 
onto the phage capsid. This spatial activity allows the precise timing of cell lysis (Hatfull, 
2001). 
 
4.2.1.1. Holins 
As mentioned above, the timing of lysis of host cells during the lytic cycle of many dsDNA 
phage is controlled by holins (Wang et al., 2000; Young et al., 2000). Holin proteins induce a 
non-specific ‘hole’ in the cytoplasmic membrane through which the endolysins can access the 
peptidoglycan (Young, 1992). The holin proteins can act in concert with heterologous 
endolysins to achieve host cell lysis, suggesting that they are not specific for their cognate 
endolysins (Rietsch and Bläsi, 1993). The holin proteins are synthesized in low amounts 
throughout the lytic cycle of phage λ, probably with an efficacy of less than one translation 
per minute per mRNA (Rolfe and Campbell, 1977; Bläsi et al., 1989; Chang et al., 1995; Nam, 
1991). During the lytic cycle, the accumulation of holin has a negligible effect on the host 
(Gründling et al., 2001; Wang et al., 2000).  
 Holins can be classified based on their membrane topologies. Class I holins have 
three transmembrane domains (TMD) with an ‘N-out’ ‘C-in’ topology, i.e. the N-terminus 
faces the periplasm, whereas the C-terminus is located towards the cytoplasm. Phage λ holin 
is an example of a class I holin, comprising 105 amino acid residues (Bläsi et al., 1999; 
Gründling et al., 2000b). Class II holins, on the other hand are shorter (65-85 amino acid 
residues) and are comprised of two TMDs in an ‘N-in’, ‘C-in’ topology, with both the N-
terminal and C-terminal domain facing towards the cytoplasm (Young, 2002). Both, class I 
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and II holins feature a highly charged C-terminal domain, generally rich in basic residues 
(Gründling et al., 2000b). The C-terminal domain of phage λ holin is non-essential for its 
function (Bläsi et al., 1999). A third type of holin is represented by class III holins. Phage T4 
encodes a class III holin, with one TMD and an exeptionally large periplasmic domain (Tran 
et al., 2005).  
During the lytic cycle ~1000-5000 molecules of the λS holin protein accumulate in the 
inner membrane (Zagotta and Wilson, 1990; Smith et al., 1998). The precision of host cell 
lysis by holin protein in phage λ is determined by yet another protein, the anti-holin. In phage 
λ, the holin and anti-holin are products of the S gene. The peculiar feature of the lambda S 
gene is the presence of two initiation codons, Met-1 and Met-3. The initiation of translation at 
Met-1 yields the anti-holin termed S107, which comprises 107 amino acids. Translation 
initiation at Met-3 gives rise to the holin protein, designated S105. Despite the fact that the 
primary gene S products differ only by the presence of Met1-Lys2 at the N-terminus of S107, 
both proteins have opposing functions (Bläsi and Young, 1996; Bläsi et al., 1990; Bläsi et al., 
1989; Raab et al., 1988). The opposing function of the S107 has been attributed to the extra 
positive charge contributed by the Lys2 residue at the N-terminus. This positive charge 
retards translocation of the N-terminal transmembrane domain (TMD1) of S107 relative to 
that of S105. As S107 and S105 form heterooligomers, these assemblies prevent formation of 
a ‘hole’ in the membrane (Gründling et al., 2000a). Dissipation of membrane potential at the 
end of the lytic cycle or artificially by energy poisons triggers translocation of the N-terminal 
TMD1 of S107 across the cytoplasmic membrane and allows formation of the lesion in which 
S105 and S107 proteins are topologically and functionally equivalent (Graschopf and Bläsi, 
1999). 
Similar to λ S, the holin gene of phage 21 has a dual start and encodes a holin (S2168) 
and an anti-holin (S2171) (Barenboim et al., 1999; Bonovich and Young, 1991). However, the 
phage 21, S2168 holin has only two transmembrane domains with a predicted N-in, C-in 
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topology (Park et al., 2006). The TMD1 of S21 is enriched with small nonpolar residues (Gly, 
Ala) and polar uncharged residues (Ser, Thr). This feature of TMD1 of S21 is unusual for 
canonical transmembrane domains, but found in the SAR domain of phage P1 endolysin (Xu 
et al., 2004). Biochemical and physiological studies have attributed the ‘hole forming activity’ 
to TMD2 of S21, thus making the 44 amino acid polypeptide the smallest known protein 
exhibiting properties of a holin (Park et al., 2006). It has been speculated that S21 is inserted 
into the cytoplasmic membrane as a hairpin structure with TMD1/TMD2 interactions. These 
interactions are thought to either mask the hydrophilic residues of TMD2 or prevent 
association of TMD2 with another TMD2 and block `hole` formation. Upon termination of 
the lytic cycle followed by membrane depolarization, the TMD1 exits from the cytoplasmic 
membrane to the periplasm similar to SAR endolysins (Xu et al., 2004; Xu et al., 2005). This 
may allow the interaction of two TMD2 domains, which in turn is facilitated by the 
interactions of two TMD1 domains in the periplasm, and consequently leads to `hole` 
formation. The functionality of the phage λ anti-holin equivalent of phage 21, S2171, is due to 
the extra positive charge at the N-terminus, which delays the exit of TMD1 to the periplasm 
relative to that of S2168 holin (Park et al., 2006). 
In contrast to the well characterized holins with either three (S105 of phage λ) or two 
(S2168 of phage 21) transmembrane domains, phage T4 has a bitopic topology with one TMD 
(Tran et al., 2005). Phage T4 holin, T, is substantially larger than the other holins with 218 
amino acid residues including 163 residues forming the C-terminal periplasmic domain 
(Wang et al., 2000). The anti-holin of phage T4, RI, shares no homology with the holin and is 
encoded by a different gene. RI inhibits the holin activity by specifically binding to T (Tran et 
al., 2005). Following superinfection of phage T4 infected cells by another T4 phage, there is 
an observed phenomenon known as `lysis inhibition` (LIN), where the normal lysis timing by 
the holin is overriden (Doermann, 1948; Hershey, 1946; Tran et al., 2005).  The LIN state is 
unstable and requires continues superinfection for its maintenance. The addition of energy 
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poisons that lead to collapse of the membrane potential completely subverts the LIN state 
(Abedon, 1994). The holin and anti-holin of phage T4 play a major role in establishing the 
LIN state in infected cells (Ramanculov and Young, 2001). The anti holin encompass an N-
terminal SAR domain, which allows it to be released to the periplasm following the primary 
infection. However, the anti-holin undergoes spontaneous inactivation and subsequent 
degradation by DegP in the absence of superinfection. Following superinfection, the ‘LIN 
signal’ is recognized by the anti-holin and this interaction stabilizes the active conformation 
of the anti-holin, which in turn binds to the holin thereby extending the lysis time (Tran et al., 
2007).     
Recently, the holin protein from phage λ, S105, was shown to be cytotoxic against 
human tumor cells and was able to reduce tumor growth in a mouse model (Agu et al., 2006). 
The λ holin was localized in the endoplasmic reticulum (ER) and mitochondria of eukaryotic 
cells. It has been speculated that similar to ‘channel-forming’ proteins encoded by human 
pathogens, λ-holin directly affects ER calcium homeostasis (Rao et al., 2004; Agu et al., 
2007). In Hela and MCF-7 cells, λ-holin caused mitochondrial membrane depolarization. The 
microscopic examination of the cell organelles revealed that mitochondria were dilated and 
rounded. The classical features associated with apoptotic cells including chromatin 
degradation was absent in λ-holin expressing cells (Kerr et al., 1995). However, a substantial 
number of double membrane-bound vesicles appeared, a characteristic feature of 
autophagosomes. Autophagosomes are well characterized in eukaryotic cells undergoing a 
non-apototic mode of cell death. Hence, λ-holin proteins are thought to mediate lysosomal 
autophagy in contrast to programmed cell death (Agu et al., 2007; Gozuacik and Kimchi, 
2004; Reggiori and Klionsky, 2005).  
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4.2.1.2. Endolysins 
The classification of phage encoded endolysins is based on the specific linkages they cleave 
in the peptidoglyacan. Endolysins include, (a) N-acetylmuramidases, (b) endo-β-N-
acetylglucosaminidases, (c) transglycosylases, (d) endopeptidases, (e) N-acetylmuramoyl-L-
alanine amidase (Fig. 5) (Young et al., 2000; Loessner, 2005; Fischetti, 2004; Fischetti, 2005). 
N-acetylmuramidases hydrolyze the β-1, 4 O-glycosidic bonds between N-
acetylmuramic acid (MurNAc) and N-acetylglucosamine (GlcNAc), thereby, reducing the 
glycan chains to disaccharide units. Phage T4 endolysin is an example of a N-
acetylmuramidases. The T4 endolysin is globular in structure, with a diameter of about 5 nm 
and exists in solution as a 14,000-Mr monomer (Creighton, 1984; Stojković and Rothman-
Denes, 2007). 
Endo- -N-acetylglucosaminidases hydrolyse the N, N’-diacetyl chitobiose of the 
asparagine linked sugar moieties of the peptidoglycan (Takegawa et al., 1989). Endolysin of 
the Streptococcus agalactiae bacteriophage B30 is an example of a N-acetylglucosaminidase 
(Huard et al., 2003; Donovan et al., 2006).  
Another class of endolysins, the transglycosylases act similar to N-acetylmuramidases, 
cleaving β-1, 4 linkages between N-acetylmuramic acid and N-acetylglucosamine residues 
(Höltje et al., 1975). Unlike muramidases, transglycosylases are not hydrolases and the 
cleavage of the β-glysocidic linkages yields 1, 6-anhydromuramyl residues (Blackburn and 
Clarke, 2001). Transglycosylases are the only class of endolysins which do not possess 
hydrolase activity (Loessner, 2005; Fischetti, 2004). The endolysin of phage ФKZ, gp144 is 
an example of phage encoded transglyosylases (Fokine et al., 2008).  
Endopeptidases cleave the peptide moiety of the peptidoglycan. The compact structure 
of the peptidoglycan is provided by the cross-linking of the backbone of the peptidoglycan 
sugar moieties by tetrapeptide linkages (Höltje, 1998). The endolysin lysH5 of the S. aureus 
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bacteriophage ΦH5 comprises endopeptidase activity, which specifically cleaves the D-
alanyl-glycyl bond specific for S. aureus peptidoglycan (Obeso et al., 2008).    
The most widely studied class of endolysins are the N-acetylmuramoyl-L-alanine 
amidases (NAM), which cleave the linkages between N-acetylmuramoyl and L-amino acid 
residues in the peptidoglycan (Hermoso et al., 2007). Phage T7 and S. aureus phage Ф11 
endolysins are examples for NAM activity (Loessner, 2005; Hermoso et al., 2007). 
The majority of the phage encoded endolysins display only one type of muralytic 
activity. However, a few phage encoded endolysins are bifunctional. The endolysin of S. 
aureus phage Ф11 harbours both, an amidase and an endopeptidase activity (Navarre et al., 
1999). The Streptococcus agalactiae phage B30 endolysin possesses a glucosaminidase and 
an endopeptidase activity (Pritchard et al., 2004). Similarly, the S. agalactiae phage NCTC 
11261 and Staphylococcus warneri M phage ФWMY endolysins display 
endopeptidase/muramidase and endopeptidase/amidase activities, respectively (Cheng et al., 
2005; Yokoi et al., 2005).  
                        
Fig. 5. Mode of action of different murein hydrolases (modified from Hermoso et al., 2007). 
Most endolysins encoded by phages infecting the Gram-positive bacteria are characterized by 
a two-domain structure, comprising a muralytic active domain and a cell wall binding domain 
(Diaz et al., 1990; Garcia et al., 1990). The N-termini of these endolysins usually harbour the 
N-acetyl muramoyl-L-alanine amidase
N-acetyl-β-D-muramidase 
N-acetyl-β-D-glucosaminidase 
Interpeptide bridge 
L-alanoyl-D-glutamate endopeptidase
Transglycosylase 
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catalytic domain, whereas the C-termini encompass the cell wall binding domain (López et al., 
1997; Fischetti, 2005).  
A few endolysins encoded by phages of Gram-positive bacteria have a multi-domain 
structure. Staphylococcal phage Ф11 endolysin has two catalytic domains linked to a single 
cell wall binding domain (Navarre et al., 1999). Streptococcus phage C1 endolysin, PlyC, is a 
multimeric protein made up of several copies of PlyCA (Catalytic domain) and PlyCB (Cell 
wall binding domain) (Nelson et al., 2006). 
The first phage endolysin with a choline binding domain (ChBP) to be crystallized 
was the Cpl-1 endolysin of pneumococcal phage Cp-1. The Cpl-1 endolysin (Fig. 6) is a 
flexible protein, where the catalytic domain and the cell wall binding domain are separated by 
a 10 amino acid hydrophilic linker sequence (Hermoso et al., 2003). The catalytic module of 
Cpl-1 has an irregular (β/α)5β3 barrel, and the cell wall anchoring module is formed by six 
similar choline-binding repeats. The choline binding domains target the endolysin to the 
choline containing teichoic acid of the pneumococcal cell wall (Hermoso et al., 2003).  
Similarly, the crystal structure of the cell wall binding domain of endolysin PlyB, 
encoded by phage BcpI reveals an irregular (β/α)5β3 barrel. The PlyB endolysin displays 
muralytic activity against B. anthracis (Schuch et al., 2002). Similar to other phage 
endolysins, PlyB encompass a bi-domain structure with a catalytic domain and a cell wall 
binding domain. The cell wall binding domain is homologous to the bacterial SH3b domain 
(Porter et al., 2007). The specific target of the SH3b domain in PlyB endolysin is not known. 
However, it has been shown that the bacterial SH3b domain from the glycyl-glycyl 
endopeptidase, ALE-1 targets penta-glycine bridges within the S. aureus peptidoglycan (Lu et 
al., 2006).  However, Bacillus spp. do not possess penta-glycine crossbridges in the 
peptidoglycan, and therefore an alternative role of the SH3b domain in saccharide binding 
cannot be excluded. 
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The activation of SAR endolysins is initiated following the membrane depolarization by 
holins. The periplasmic membrane-bound SAR endolysins exit the bilayer in an active form. 
Although the process of the activation of SAR endolysins is not fully understood, it has been 
speculated that an intramolecular disulfide isomerization causes its activation (Xu et al., 
2005). The SAR endolysins from phage Mu, T1, P1 and phage 21 appear to make use of the 
same strategy of intramolecular disulfide isomerization for activation (Hermoso et al., 2003).  
 
 
 
Fig. 6. Three-dimensional structure of the Cp1-1 endolysin showing both the catalytic and the 
cell wall binding domain (Hermoso et al., 2007). 
4.2.2. S. aureus bacteriophages 
4.2.2.1. Phage Twort 
S. aureus bacteriophage Twort belongs to the family of myoviridae. There are two genes in 
phage Twort required for the host cell lysis, holTW and plyTW. HolTW shares homology with 
ORF3, a putative holin of prophage Ф11 (Weerakoon and Jayaswal, 1995). Several features 
of the holin protein families are shared by HolTw. These include, (a) two membrane spanning 
domains, (b) a β-turn linker separating the antiparallel transmembrane domains, (c) a charged 
C-terminal domain (Young and Bläsi, 1995). The holTw encodes a 185 aa protein and 
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overlaps with plyTW (encodes endolysin) by 35 bp but in a different reading frame, 
suggesting translational coupling of the two genes. PlyTW shares significant homology to the 
LytA amidase of Ф11 (42% identity). The C-terminal domain of PlyTW shares high degree of 
homology with the C-terminus of lysostaphin. HolTw complements a lambda S gene mutation 
(Loessner et al., 1998). 
 
4.2.2.2. Phages Ф11, Ф12 and Ф13 
Phages Ф11, Ф12 are dsDNA phages which utilize a unique holin-endolysin system to 
achieve host cell lysis. The endolysins encoded by both Ф11 and Ф12 are comprised of three 
domains. The N-terminal region comprises the endopeptidase domain (CHAP), cleaving the 
D-alanyl-glycyl linkage. The central region of the endolysin harbours the amidase domain 
which cleaves the N-acetyl-muramoyl-L-alanine linkage. The C-terminal region contains the 
cell wall binding motif which comprises a SH3b domain (Baba and Schneewind, 1996; Sass 
and Bierbaum, 2007).  
 Phage Ф13 is a dsRNA temperate phage with a genome of 42.7 kb and belongs to 
serogroup F (Carroll et al., 1995). Phage Ф13 mediates a negative effect on β-hemolysin gene 
expression and a postive effect on staphylokinase production. The negative effective on β-
hemolysin expression is achieved by phage integration into the host attB site, which is located 
within the β-hemolysin gene, hlb (Carroll et al., 1993). Phage Ф13 carries a gene for 
staphylokinase. The expression of this gene contributes to the formation of a phenotype with 
increased staphylokinase production and thereby to an increased virulence of the host (Zou et 
al., 2000). The staphylokinase activity leads to the formation of plasmin from plasminogen, 
which in turn digests fibrin clots, thereby facilitating a spreading of the infection. Furthermore, 
staphylokinase cleaves immunoglobulin G (IgG) and the complement component, C3b 
(Bokarewa et al., 2006). 
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4.2.2.3. Phage 187 
Phage 187 differs from all other S. aureus phages in its host range, distinctive virions and its 
DNA restriction pattern (Lee and Stewart, 1985; Loessner et al., 1999). Phage 187 recognizes 
a distinctive teichoic acid (galactosamine ribitol teichoic acid) (Karakawa and Kane, 1971). In 
contrast to the lysis gene organization of other S. aureus phages, where holin genes overlap 
with endolysin genes, in phage 187 the holin gene is fully embedded in the 5’ region of the 
endolysin gene ply187. The N-terminal domain of phage 187 endolysin, Ply187, harbours the 
muralytic active domain and is thought to act as an N-acetylmuramoyl-L-alanine amidase due 
to its significant homology to LytA of phage Ф11 (Wang et al., 1991). 
 
4.2.2.4. Phage 68 
Phage P68 (Fig. 7) belongs to the family of podoviridae, which consists of the smallest known 
dsDNA phages (Tao et al., 1998). Phage P68 comprises an isometric head with a short non-
contractile tail of ~ 40 nm in length. The pre-neck appendage of phage 68 is a hallmark of 
‘Φ29-like phages’. The total G+C content of the genome of phage 68 is 29.3%. Identical 
inverted terminal sequence repeats with a length of 210 bp were found at the end of the DNA. 
There are 22 open reading frames (ORF) within the genome of phage 68, out of which 12 are 
organized in an opposite direction. The lysis gene cassette of phage 68 comprises ORF15, 
which encodes the holin and ORF16, encoding the endolysin. Interestingly, the holin gene is 
almost completely embedded (overlap of 253 bp) within the endolysin gene (Vybiral et al., 
2003).  
 
Fig. 7. Electron micrograph of the phage P68 negatively stained with 2% uranyl acetate 
(Vybiral et al., 2003). 
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4.2.2.4.1. Phage 68 endolysin (Lys16) 
The endolysin gene (ORF16) of phage P68 shows significant similarity to the endopeptidase 
domain of the S. aureus phage Twort endolysin (Loessner, et al., 1998) and to the endolysin 
of phage Φ11 (Wang et al., 1991). The endolysins of phage Twort and Φ11 encompass three 
domains composed of an N-terminal D-alanyl-glycyl endopeptidase domain, a central N-
acteylmuramoyl-L-alanine amidase domain and a C-terminal cell-wall-targeting domain. 
However, the endolysin of phage P68, Lys16 lacks the central N-acteylmuramoyl-L-alanine 
amidase domain found in Twort and Φ11 endolysins (Fig. 8) (Navarre et al., 1999). A 
significant homology of 43% and 57% respectively, was found between the N-terminal 112 
amino acids of P68 Lys16 with the inferred D-alanyl-glycyl endopeptidase domains of the 
Twort and the Φ11 endolysins. The C-terminal domain of P68 Lys16 is homologous to the 
cell-wall-targeting domains of both the Twort and Φ11 endolysins (Takáč et al., 2005).  
        
 
Fig. 8. Proposed domain organization of phage P68, Twort and Φ11 endolysins (Navarre et al., 
1999; Takáč et al., 2005) 
 
D-alanyl glycyl endopeptidase domain     Cell wall binding domain
Endolysin of phage P68 
Endolysin of phages Twort and Φ11 
D-alanyl glycyl endopeptidase domain             amidase domain                            Cell wall binding domain 
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4.2.2.4.2. Phage 68 protein 17 
The cell-puncturing device of lytic phages functions to penetrate the outer membrane of the 
host bacteria by locally dissolving the peptidoglycan to allow injection of the phage genome 
(Arisaka et al., 2003). In phage T4, protein 5 is located on the phage tail and forms a member 
of the cell-puncturing complex (Kao and McClain, 1980; Nakagawa et al., 1985). In phage 
P68, protein 17 is part of the phage virion (Takáč and Bläsi, 2005). Protein 17 shows 45% 
similarity within a 487 amino acid overlap to the product of ORF56 of the temperate S. aureus 
phage φETA (Yamaguchi et al., 2000) as well as to ORF636 of the S. aureus temperate phage 
φSLT (Narita et al., 2001) within a 558 amino acid overlap. These two proteins share 
similarity with the minor structural protein gp89 of L. delbrueckii bacteriophage LL-H 
(Mikkonen et al., 1996). Similar to phage T4 protein 5, protein 17 of phage 68 displayed 
muralytic activity against S. aureus peptidoglycan (Labedan and Goldberg, 1979; Taká  and 
Bläsi, 2005). It has been suggested that the lysozyme activity of protein 5 digests the 
peptidoglycan locally, allowing the T4 tail tube to penetrate the periplasmic space and 
henceforth allowing the infection process to be completed (Kao and McClain, 1980; Mosig et 
al, 1989; Nakagawa et al, 1985). The substrate specificity of protein 5 is similar to that of T4 
gpE lysozyme, which is a N-acetylmuramidase (Kanamaru et al., 1999). It has also been 
demonstrated that the L. lactis phage Tuc2009 tail tip protein Tal2009 has muralytic activity. 
Tal2009 appears to undergo autocatalytic processing, which was attributed to its endopeptidase 
activity (Kenny et al., 2004). In contrast to the Tal2009 protein, there is no evidence for a 
putative protease motif in protein 17 (Takáč and Bläsi, 2005). Protein 17 recognizes a 
different receptor with respect to phage P68 on S. aureus. It has been speculated that protein 
17 targets a carbohydrate moiety found in the S. aureus cell wall (Takáč and Bläsi, 2005). 
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4.3. Enzybiotics 
The term enzybiotic has been coined for phage encoded endolysins that are capable to lyse 
bacteria when added exogenously (Veiga-Crespo et al., 2007; Nelson et al., 2001; Zimmer et 
al., 2002). The local degradation of the exposed peptidoglycan of Gram-positive bacteria 
results in lysis since the cytoplasmic membrane can not withstand the osmotic pressure of the 
cytoplasm (Fischetti, 2006).  
 
4.3.1. Enzybiotics against pathogenic bacteria 
Several recent studies suggest that enzybiotics can be used to treat bacterial infections. These 
include, the therapeutic application of purified phage endolysin against Streptococci in mice 
(Nelson et al., 2001; Loeffler et al., 2001) and against several other Gram-positive pathogens 
including Enterococcus faecalis and E. faecium (Yoong et al., 2004), Clostridium perfringens 
(Zimmer et al., 2002), group B Streptococci (Cheng et al., 2005) and B. anthracis (Schuch et 
al., 2002). Bacteriophage Cp-1 encoded endolysin, Cpl-1, was active against Streptococcus 
pneumoniae in a murine sepsis model (Jado et al., 2003). A single dose of CpI-1 (1100U) 
endolysin administrated intraperitoneally rescued the mice challenged with S. pneumoniae 
(Jado et al., 2003). Similarly, the endolysin from a phage infecting group C streptococci was 
efficient in the prevention and elimination of group A Streptococci from the upper respiratory 
tract of mice (Nelson et al., 2001).  
Endolysin PlyC from phage γ was effective against B. anthracis in vitro and in vivo. 
The capsule of B. anthracis did not prevent the access of PlyC to the cell wall. The 
intraperitonial injection of B. anthracis in mice was fatal and caused the death of mice within 
5 h or less. However, treatment of the mice with PlyC (50U) intraperitoneally 15 min 
following infection had a significant theraupeutic effect, rescuing 68.4 % of the infected mice 
(Schuch et al., 2002). 
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4.4. The prokaryotic ribosome 
The protein biosynthesis is an important and complex process which is performed by a large 
ribonucleoprotein machinery, the ribosome. The prokaryotic ribosome (70S) has a mass of 
approximately 2.6-2.8 MDa and encompasses two distinct subunits, the small 30S subunit and 
the large 50S subunit (Fig. 9), each composed of rRNA and proteins. In the recent years, the 
structure of the ribosome has been determined at atomic resolution (Selmer et al., 2006). 
These data support the biochemical studies, which indicate that the catalytic activities of the 
ribosomes are mainly performed by the rRNA. It therefore is termed a protein-stabilized 
ribozyme (Culver, 2003). The 30S subunit has a molecular weight of approx. 0.85 MDa and is 
involved in decoding of the mRNA based genetic code into the amino acid sequence of a  
protein, using adaptor molecules known as transfer RNAs (tRNAs) (Laursen et al., 2005). It is 
composed of 16S rRNA (ribosomal RNA, Fig. 10) and 21 proteins designated S1-S21. It 
contains the messenger decoding-site and mediates the interaction between messenger RNA 
(mRNA) and transfer RNA (tRNA). The 50S subunit consists of two RNA molecules, the 5S 
and 23S rRNAs, and 34 associated proteins. During protein synthesis it catalyzes peptide 
bond formation at the peptidyl transferase center, which is formed exclusively by the 23S 
rRNA. The 50S subunit harbors the sites of interaction with several GTP binding proteins, 
which assist in various translational processes such as initiation, elongation and termination. 
The 5S rRNA with a size of 120 nt acts as a seventh domain of the 50S subunit and confers 
stability to its structure (Sergiev et al., 2000).  
There are three functional sites on the ribosome where tRNAs bind: (i) The A-site is 
where the decoding takes place. Here, the correct aminoacyl-tRNA is selected based on its 
codon-anticodon interaction, respective to the codon of the mRNA currently displayed (ii) 
The P-site, where the peptidyl tRNA is located, carrying the elongating polypeptide chain (iii) 
The E-site, or the exit site, harboring the deacylated tRNA, ready to exit the ribosome (Fig. 
11).  
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Fig. 9. Composition of the E. coli ribosome (modified from Iskakova, 2005). 
 
                 
Fig. 10. Structure of the16S rRNA. (A) The 3D structure of the 16S rRNA. (B) Three-
dimensional fold of 16S rRNA in 70S ribosomes (Yusupov et al., 2001). The colors are 
identical to (A). Blue: domain I; violet: domain II; Red: domain III; yellow: domain IV.   
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Fig. 11. The location of A (violet), P (green) and E (yellow) site tRNAs in the 50S and 30S 
ribosomal subunit (Frank, 2003). 
4.5. Protein synthesis 
During protein synthesis a single ribosome can incorporate 10-20 amino acids (aa) per second 
(Bremer and Dennis, 1996). The accuracy of aa incorporation is very high having only one 
misincorporation per 3000 aa (Bouadloun et al., 1983). The process of protein synthesis can 
be divided into four consecutive phases: initiation, elongation, termination and ribosome 
recycling (Fig. 12).  
 
4.5.1. Initiation 
Translation initiation is the rate limiting step in protein synthesis. During initiation, the 
ribosome, the aminoacylated and formylated initiator tRNA (fMet-tRNAfMet), the mRNA, and 
intiation factors IF1, IF2 and IF3 are involved (Laursen et al., 2005). Initially, the anti-Shine 
Dalgarno (anti-SD) sequence on the 3’-end of 16S rRNA interacts with the Shine Dalgarno-
sequence (SD) of the mRNA, thereby facilitating the positioning of the 30S subunit on the 
30S 50S 
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ribosome binding site on the mRNA. Following the SD-anti-SD interaction, the initiator 
tRNA is bound to the P-site of the 30S subunit in three steps, codon-independent binding, 
codon-dependent binding and fMet-tRNAfMet adjustment (Tomsic et al., 2000; Laursen et al., 
2005). These steps are promoted by IF2, which directly interacts with fMet-tRNAfMet and the 
ribosome. In addition, IF2 also prevents the binding of the aminoacylated elongator tRNAs 
during ternary complex formation (Gualerzi and Pon, 1990; Hartz et al., 1989). Furthermore, 
the binding of the fMet-tRNAfMet to the P-site is stabilized by IF3 (Gualerzi et al., 1977). IF3 
acts as fidelity factor in translation initiation. It selectively destabilizes non cognate start 
codon-anti-codon interaction by directly associating with the ribosome, anti-codon and fMet-
tRNAfMet (Subramanian and Davis, 1970; Gualerzi et al., 1971; Sussman et al., 1996; Hartz et 
al., 1990; Gold, 1988; Yusupov et al., 2001; La Teana et al., 1995).  In addition, IF1 
participates in initiation complex formation by specifically binding to the A-site of the 30S 
subunit. It is suggested to block the A-site and thereby it positions the initiator tRNA towards 
the P-site (Carter et al., 2001; Dahlquist and Puglisi, 2000). The unstable pre-initiation 
complex comprising the 30S subunit, IF1, IF2, IF3, mRNA and fMet-tRNAfMet, which is 
bound to the P site by a codon-independent manner undergoes a confirmational change which 
facilitates the codon-anticodon interactions leading to a stable 30S initiation complex (Pon 
and Gualerzi, 1984). Following the formation of the stable 30S initiation complex, IF1 and 
IF3 dissociate and, upon GTP-hydrolysis catalysed by IF2, the association of the the large 50S 
subunit to the 30S initiation complex is stimulated. This leads to the formation of the 70S 
initiation complex the release of IF2 (Marzi et al., 2003). However, GTP hydrolysis is neither 
essential for the interaction with the initiator tRNA and IF2 nor required for the formation of 
the initiation complex (Petersen et al., 1979).  However, it is speculated that the GTP-
hydrolysis is required for the correct adjustment of the fMet-tRNAfMet in the P site (La Teana 
et al., 1996). The 70S initiation complex with the initiator tRNA located in the P site 
 34
consequently enters the elongation cycle (Boelens and Gualerzi, 2002; Gualerzi et al., 2000; 
Gualerzi and Pon, 1990; Sonenberg et al., 2000; Sørensen et al., 2001).  
 
 
 
 
4.5.2. Elongation 
The elongation of the nascent peptide by one aa according to the corresponding codon on the 
mRNA is performed by the ribosome in a cyclic manner (Vesper and Nierhaus, 2004). Two 
main elongation factors, EF-Tu and EF-G are involved in the elongation cycle, which can be 
divided into three important steps: (i) A-site occupation, (ii) peptide bond formation, and (iii) 
translocation. The A-site occupation can be subsequently divided into two reactions. In the 
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Fig. 12. Protein synthesis in bacteria (modified from Iskakova, 2005) 
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first reaction, the EF-Tu associated with GTP and the aminoacyl-tRNA (ternary complex) (aa-
tRNA.EF-Tu.GTP) is recruited to the A-site based on the codon-anti-codon interaction. 
Following the delivery of the aa-tRNA to the A-site, the GTPase center of EF-Tu is activated 
leading to the GTP hydrolysis and release of the EF-Tu.GDP complex from the ribosome. The 
second reaction is known as the accommodation step, wherein the release of the EF-Tu.GDP 
from the ribosome allows the aa-tRNA to be bound to the A-site by docking the aminoacyl 
residue of the aa-tRNA to the peptidyl transfer center (PTC) of the 50S subunit. The A and P 
site occupied aminoacyl tRNAs are now ready for the formation of the peptide bond. This 
state of the ribosome is called the ‘pre-translocational’ state (PRE) (Vesper and Nierhaus, 
2004). The second step of the elongation cycle is the peptide bond formation between the 
peptidyl residue of the donor (P-site) and the aminoacyl residue of the acceptor (A-site) 
(Vesper and Nierhaus, 2004). This leads subsequent formation of a peptidyl-tRNA at the A-
site and a deacylated tRNA at the P-site. The third and final step of the elongation cycle is the 
translocation. During translocation, the tRNAs located in the A-site and P-site change their 
position. Precisely, the peptidyl-tRNA at the A-site moves to the P-site and the deacylated 
tRNA of the P site moves to the E site. This state of the ribosome is called the ‘post-
translocational state’ (Vesper and Nierhaus, 2004). The P- and E-sites of the ribosome are 
occupied and the A-site is vacant and waits to receive the new aa-tRNA.EF-Tu.GTP ternary 
complex based on the codon on the mRNA, thus the elongation cycle is repeated. However, 
during the next A-site occupation the E site tRNA has to be released (Vesper and Nierhaus, 
2004). This movement of the tRNA.mRNA complex within the ribosome by one codon is 
catalyzed by elongation factor G (EF-G) (Spahn and Nierhaus, 1998; Wilson and Noller, 
1998). 
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4.5.3. Termination 
The termination of protein synthesis occurs when a stop codon (UAA, UAG or UGA) is 
located in the A-site of the ribosome. This process is followed by the subsequent hydrolytic 
release of the completed polypeptide from the peptidyl-tRNA catalyzed by release factors 
RF1 and RF2. Subsequently, RF3 stimulates the termination process in a GTP-dependent 
manner, thereby releasing RF1 and RF2 from the post-termination complex (Freistroffer et al., 
1997; Zavialov et al., 2001). However, RF3 has been shown not to be essential in E. coli. 
 
4.5.4. Ribosome recycling 
Ribosome recycling is regarded as the fourth step in protein synthesis. Upon termination of 
protein synthesis the ribosome recycling factor (RRF) -in conjunction with EF-G and IF3- 
promotes the dissociation of the ribosome into its subunits. Since an RRF deficient E. coli is 
not viable, dissociation of the ribosomes is suggested to be essential for cell growth (Janosi et 
al., 1998). EF-G performs distinct functions in protein synthesis including translocation and 
ribosome dissociation. During both processes, EF-G hydrolyses GTP to GDP and Pi. The 
translocation step is less dependent on GTP hydrolysis by EF-G. However, the ribosome 
disassembly by the RRF and EF-G is blocked when GTP is replaced by a non-hydrolyzable 
analog of GTP (Rodnina et al., 1997; Peske et al., 2005; Zavialov et al., 2005). Recently, it 
was shown that the Pi released during GTP hydrolysis is important for ribosome dissociation 
(Savelsbergh et al., 2009). The binding of EF-G to the RRF bound ribosome triggers an inter-
domain rotation of RRF, which destabilizes two strong intersubunit bridges of the ribosome 
(B2a and B3), consequently separating the two subunits (Gao et al., 2007).  Upon dissociation 
of the ribosomal subunits, IF3 binds to the 30S subunit, thereby preventing reassociation 
(Hirashima and Kaji, 1973; Peske et al., 2005; Zavialov et al., 2005; Vesper and Wilson, 
2006). 
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4.6. Ribosomal proteins S1 and S2 
Protein S1 is the largest protein in the Escherichia coli ribosome and has a molecular mass of 
61 kDa. It associates to the 30S subunit during late stage of ribosome biogenesis 
(Subramanian, 1983; Sharma et al, 2005). In Gram-negative bacteria, protein S1 plays an 
essential role in the translation initiation. It interacts with a pyrimidine-rich region within the 
mRNA upstream of the SD-sequence (Boni et al., 1991, Sengupta et al., 2001), thereby 
increasing the concentration of the translational start site in the vicinity of the decoding site on 
the ribosome. In addition, protein S1 has been suggested to assist in positioning of the 30S 
subunit in close proximity to the translational start site by destabilizing secondary structures 
(de Smit and van Duin, 1994). Therefore, S1 is indispensable for the translation of canonical 
mRNAs and is therefore essential for E. coli and likely of all Gram-negative bacteria 
possessing a S1 homologue (Sørensen et al., 1998). However, for the translation of leaderless 
mRNAs lacking a 5’ UTR protein S1 is dispensable (Moll et al., 2002a and b). Furthermore, it 
has been suggested to play a role in translation elongation (Potapov and Subramanian, 1992). 
In addition to its function in the initiation of protein synthesis it has been reported to be 
involved in the rescue of stalled ribosomes via the tmRNA mediated trans-translation (Saguy 
et al., 2007; Qi et al., 2007). In this process, where a degradation tag is added to the 
incomplete peptide bound to the stalled ribosome (Muto et al., 2000; Withey and Friedman, 
2003), the tmRNA functions as both, tRNA and mRNA (Qi et al., 2007).  
S1 consists of six consecutive motifs (Fig. 13; Bycroft et al, 1997). The two N-
terminal motifs of S1 are required for binding to the small ribosomal subunit. The four C-
terminal motifs of approximately 70aa in length are facing to the solvent side of the ribosome. 
They are involved in interaction with mRNAs and tmRNAs at single stranded RNA and RNA 
pseudoknots (Giorginis and Subramanian, 1980; Ringquist et al., 1995). In addition, it has 
been shown that the extreme C-terminal domain of ribosomal protein S1 is involved in the 
autogenous regulation of the S1 expression (Boni et al., 2000). 
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Some of the peculiar features of ribosomal protein S1 include the acidity of the protein. All 
other ribosomal proteins except the two large subunit proteins, L7/L12 are basic. In addition, 
S1 is the only protein which binds to the ribosome by protein-protein interaction (Boni et al, 
1982). Supporting this observation, cross-linking experiments and X-ray crystallographic 
studies demonstrated that protein S2 is located in close proximity to S1 on the ribosome 
(Sengupta et al, 2001; Laughrea and Moore, 1978; Bollen et al, 1979). In addition, studies by 
Moll et al (2002b) revealed that ribosomes devoid of protein S2 also lack S1. These results 
indicate that protein S2 is essential for binding of protein S1 to the 30S ribosomal subunit.   
 
Fig. 13. Domain organization of protein S1 of E. coli 
Ribosomal protein S2 is the second largest protein associated with the 30S subunit 
(Fig. 14). It is a highly conserved protein throughout all domains of life and is indispenble for 
translation in prokaryotes, eukaryotes, chloroplasts and mitochondria (Ardini et al., 1998; 
Wilson and Nierhaus, 2005). In prokaryotes, protein S2 is suggested to protect and stabilize 
the SD- anti-SD duplex located between the head and platform of the 30S subunit (Kaminishi 
et al., 2007). Structural analyses have shown that S2 is a slightly elongated protein with a 
two-domain organization that has been shown to be more sensitive to proteolytic cleavage 
compared to other ribosomal proteins under the same conditions (Georgalis et al., 1981; 
Wittmann et al., 1980; Wimberly et al., 2000; Brodersen et al., 2002). During ribosome 
assembly protein S2 binds to the 30S subunit at a very late step (Culver, 2003). However, 
D1 D2 D3 D5 D4 D6 
 1                    2                      3                   4                    5                    6   
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protein S2 binds to the 16S rRNA (Mizushima and Nomura, 1970; Culver, 2003) and can be 
cross linked to ribosomal proteins S1, S3, S5 and S8 (Littlechild et al., 1977; Traut et al., 
1980).   
 
                                                   
Fig. 14. Proposed position of protein S1 (Red) and S2 along with other ribosomal proteins in 
the 30S subunit (Sengupta et al., 2001). 
4.7. Antibiotics targeting the ribosomes 
Due to the high complexity of the ribosome it represents a major target for clinically relevant 
antibiotics (Gale et al., 1981). As the rRNA, which is responsible for most of the pivitol steps 
in protein synthesis, accounts for most of the contacts with antibiotics (Yonath, 2005), they 
target functionally important sites within the ribosome, like (i) the decoding site within the 
30S subunit (paromomycin and streptomycin, Brodersen et al., 2000), (ii) the mRNA tunnel 
(edeine and spectinomycin, Carter et al., 2000; Pioletti et al., 2001; Brodersen et al., 2000), 
(iii) the A-site of the 30S subunit (tetracycline; Pioletti et al., 2001), (iv) the peptidyl transfer 
center (PTC) in the 50S subunit (chloramphenicol and sparsomycin, Pioletti et al., 2001; 
Schlünzen et al., 2001, Hansen et al., 2003), and (v) the protein exiting tunnel 
(troleandomycin, Berisio et al., 2003).   
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The 30S subunit is primarly targeted by pactamycin, tetracyclines and aminoglycoside 
antibiotics. Pactamycin is a cyclopentane derivative that interacts with helix H23b and the 
helix H24a of the 16S rRNA, close to the tRNA binding cleft (Brodersen et al., 2000). It 
mimics the di-nucletotide of the mRNA in the E-site, which suggests that it blocks the path of 
movement of mRNA through the ribosome. Pactamycin does not interfere with initiation, 
subunit association or tRNA binding to the A-site. However, the translocation of A- and P-site 
tRNA to the P- and E-site seems to be affected (Dinos et al., 2004). 
 
4.7.1. Aminoglycoside antibiotics 
Aminoglycoside antibiotics are produced by Streptomycetes and generally composed of a 
sugar moiety and an amino group. They are the most commonly used antibiotics as clinical 
therapeutics, like gentamicin, streptomycin, neomycin, and kanamycin. Aminoglycosides 
mainly target the 30S ribosomal subunit, where they usually bind to the 16S rRNA (Shakil et 
al., 2008). They specifically bind to the A-site internal loop within the deep groove of helix 
44 of the 16S rRNA in the highly conserved region of the decoding center (Carter et al., 2000), 
where they interfere with two flexible adenine residues (A1492, A1493; Ogle et al., 2001). 
These residues are involved in the selection of the cognate aminoacyl tRNA during elongation. 
Consequently, these antibiotics affect the fidelity of protein translation (Moazed and Noller, 
1987; Fourmy et al., 1996; Carter et al., 2000; Pape et al., 2000). Taken together, 
aminoglycoside antibiotics seem to act as rigid molecular braces that prevent conformational 
changes important for ribosome function.    
Kasugamycin (Ksg), was shown to prevent the formation of the pre-initiation complex 
by interfering with fMet-tRNAf, which binds to the ribosomal P-site in E. coli ribosomes 
(Poldermans et al., 1979; Woodcock et al., 1991). In addition, recent studies have shown that 
treatment of the E. coli cells with Ksg in vivo leads to the formation and accumulation of 
stable 61S ribosomal particles. These particles comprise an intact 50S subunit. However, 
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many proteins of the small subunit were absent (Kaberdina et al., 2009). In addition, it has 
been shown that erythromycin affects the assembly of 50S subunit and the paromycin and 
neomycin inhibit 30S assembly in S. aureus (Chittum and Champney, 1995; Mehta and 
Champney, 2003).  
 
4.7.2. Polyketide antibiotics 
Polyketides are usually secondary metabolites of bacteria, fungi, animals or plants formed by 
the polymerization of propionyl or acetyl subunits by claisen condensation (Robinson, 1991). 
Tetracycline is one among the most commonly used polyketide antibiotics.  It belongs to the 
octahydronaphtacene derivatives with an overall L-shape structure. Several binding sites of 
tetracycline on the 30S subunit have been identified by crystallographic studies (Pioletti et al., 
2001; Brodersen et al., 2000). The drug interacts with the shallow groove of the helix H34, 
including contacts to helix H31. This interaction prevents binding of the aminoacyl-tRNA to 
the A-site, consequently leading to the inhibition of the first step in elongation (Pioletti et al., 
2001; Brodersen et al., 2000). 
 
4.8. Bacterial resistance towards antibiotics 
Bacterial resistance to antibiotics is a common problem in modern therapeutics. The mode of 
resistance is created by random mutations in a gene of bacteria and in turn evolved by natural 
selection. Resistance of bacteria against antibiotics could also be a result of horizontal gene 
transfer (Berglund and Söderquist, 2008). The most common nature of resistance towards β-
lactam antibiotics is by enzyme catalyzed chemical modification (Wright et al., 1998; 
Mingeot-Leclercq et al., 1998; Kotra et al., 2000). The resistance against tetracycline which 
belongs to polyketide antibiotic group occurs by efflux pump, ribosomal protection and 
enzymatic degradation (Chopra and Roberts, 2001). The resistance towards antibiotics 
targeting the ribosomes is usually achieved through point mutations within the rRNA. For 
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instance, the resistance to streptomycin is achieved by point mutations in the 16S rRNA gene 
(505U→526A, 506A→525U and 507U→524A), which confer resistance to the drug but do 
not affect the functionality of the ribosome (Springer et al., 2001). Likewise, the resistance to 
other aminoglycoside antibiotics such as neomycin, kanamycin and gentamicin is conferred 
by point mutations in the 16S rRNA gene (De Stasio et al., 1989; Beauclerk and Cundliffe, 
1987). Resistance against kasugamycin is caused by the lack of di-methylation of two 
adjacent adenosines positioned at nucleotides 1518/1519 in helix 45 at the 3’-end of the 16S 
rRNA (Helser et al., 1971). This post-transcriptional modification has been shown to alter the 
conformation and flexibility of the ultimate stem-loop in 16S rRNA (Rife and Moore, 1998).  
 
4.9. The S1-S2 interaction: A new target for antimicrobials 
As mentioned above, several chemically diverse antibiotics target the ribosome at a few 
locations, which results in an overlap of their binding sites.  As a consequence, a single 
mutation in the 16S rRNA gene can potentially confer resistance to several antibiotics 
(Skinner et al., 1983).  Moreover, these binding sites are predominantly localized in regions 
of conserved function(s) in eukaryotic, bacterial as well as in mitochondrial ribosomes.  
Therefore, these drugs can have adverse side effects when used as clinical therapeutics.  Thus, 
there is need for alternative antimicrobials, which do not interfere with ribosome function, but 
inhibit assembly of functionally important proteins. In contrast, any mutation interfering with 
such a protein-protein interaction would be detrimental to cell growth of bacteria.  It is 
therefore conceivable, that resistance mechanisms towards drugs, which are based on an 
alteration of the drug target site (i.e. protein-protein interaction sites), are more difficult to 
develop as point mutations in 16S rRNA.  Taken together with the semi-selective action 
against Gram-negative pathogens, such antimicrobials could be advantageous over 
conventional antibiotics. 
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In the past decades, major progress in drug development has been made by using a binding-
pocket model of drug targets.  Small molecules were designed to fit into substrate binding 
sites of proteins.  Since it was easier to screen for low molecular weight inhibitors that block 
their active sites, in principal enzymes have been used as therapeutic drug targets (Arkin and 
Wells, 2004).  However, given that specific protein-protein interactions are essential in most 
biological processes, they represent likewise promising opportunities for therapeutic 
intervention based on selective inhibition of these interactions.  For example, highly specific 
protein-protein interactions in bacteria that are not found in human hold promise for treatment 
of infectious diseases (Arkin and Wells, 2004).  As S1 is essential for translation initiation in 
E. coli and probably in most Gram-negatives, and requires S2 for binding to the ribosome, the 
studies aiming at identifying novel antimicrobials, which specifically inhibit the S1-S2 
interaction, would prove to be fruitful.  In contrast, there is no functional S1 homologue in the 
low “GC” group of Gram-positive bacteria, which include beneficial commensals such as 
probiotic lactic acid bacteria (Vellanoweth and Rabinowitz, 1992).  In addition, mitochondria 
lack functional homologues of ribosomal protein S1 (Vellanoweth and Rabinowitz, 1992; 
Cavdar-Koc et al., 2001) and eukaryotic ribosomes employ different mechanisms for 
translation initiation (Marintchev and Wagner, 2004).  Therefore, a drug, which interferes 
with the S1-S2 interaction, would act selectively against a number of pathogenic Escherichia 
coli strains.  Given that protein S1 is highly conserved in the gamma subdivision of 
proteobacteria, this drug has the potential to act as well as an antimicrobial against other 
Gram-negative bacterial pathogens, including Pseudomonas aeruginosa, Salmonella enterica 
and Klebsiella pneumoniae.   
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5. Aim of the study 
The first aim of the study was to develop a specific enzybiotic against S. aureus. The strategy 
for developing a novel antimicrobial agent against Gram positive S. aureus included the 
genetic engineering of bacteriophage P68 endolysin with the aim to increase the solubility of 
the enzybiotic.  
The second aim targets towards the design of an antimicrobial compound affecting 
ribosome assembly in Gram-negative bacteria. As mentioned above, the interaction between 
the two ribosomal proteins S1 and S2 has the potential to represent a target site for 
antimicrobial activity. A drug, which would disrupt the S1/S2 interaction, could thus act semi-
selectively against Gram-negative pathogens. In order to verify the interaction of proteins S1 
and S2, a yeast-two-hybrid analysis has been performed. In addition, a random mutagenesis 
study has been performed to elucidate the amino acid residues involved in the S1/S2 
interaction.  
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Phage lytic enzymes (enzybiotics) have gained attention as prospective tools to eradicate Gram-positi
pathogens resistant to antibiotics. Attempts to purify the P16 endolysin of Staphylococcus aureusphage P
wereunsuccessful owing to thepoor solubilityof theprotein. Toovercome this limitation,weconstructe
chimeric endolysin (P16-17) comprised of the inferred N-terminal d-alanyl-glycyl endopeptidase doma
and the C-terminal cell wall targeting domain of the S. aureus phage P16 endolysin and the P17 minor coBacteriophage
Enzybiotic
G
S
protein, respectively. The domain swapping approach and the applied puriﬁcation procedure resulted
in soluble P16-17 protein, which exhibited antimicrobial activity towards S. aureus. In addition, P16-17
augmented the antimicrobial efﬁcacy of the antibiotic gentamicin. This synergistic effect could be useful
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taphylococcus aureus to reduce the effective dos
. Introduction
Host cell lysis by double-stranded DNA phage is generally
chieved by a phage encoded holin in conjunction with a muralytic
nzyme (endolysin). In general, the holin induces a non-speciﬁc
esion in the cytoplasmic membrane, which allows the endolysin
o degrade the peptidoglycan at a genetically programmed time
fter infection (Young, 1992). Ancillary proteins can either serve
s negative regulators of the holin, or act by destabilizing the
uter membrane (Young and Bläsi, 1995; Wang et al., 2000). The
ndolysins are enzymes with broad activities cleaving either gly-
osidic, amide, or peptide bonds of the peptidoglycan (Young,
992). The phage encoded endolysins are principally synthesized
ithout a signal sequence and accumulate fully folded and active
n the cytosol. However, a few endolysins exploit the host sec
ystem to reach the peptidoglycan. These endolysins bear a N-
erminal SAR (signal arrest release) sequence by which they are
ethered to the outer site of the inner membrane until the mem-
rane potential is dissipated by the holin (Xu et al., 2005). In
ontrast to Gram-negative bacteria, endolysins can act as exolysins
n Gram-positive bacteria, of which the peptidoglycan is exter-
ally accessible (Garcia et al., 1987; Fischetti, 2003; Loessner, 2005).
uriﬁed phage endolysins have been used as therapeutics against
treptococci in mice (Nelson et al., 2001; Loefﬂer et al., 2001), and
ave been proven effective against other Gram-positive pathogens
ncluding Enterococcus faecalis and E. faecium (Yoong et al., 2004),
lostridium perfringens (Zimmer et al., 2002), group B Streptococci
∗ Corresponding author. Tel.: +43 4277 54609; fax: +43 4277 9546.
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Cheng et al., 2005) and Bacillus anthracis (Schuch et al., 2002). The
erm enzybiotics has been coined to classify these antimicrobials
Nelson et al., 2001; Hermoso et al., 2007).
In addition to classical endolysins,which are synthesized during
hage infection, phage virion proteins can as well exert muralytic
ctivity. These virion associated murein hydrolases are believed to
acilitate the entry of phage DNA during infection. The presence of
uch activities has been previously reported for the Staphylococcus
ureus phage 11 and 85 (Moak and Molineux, 2004), for the
actococcus lactis phage Tuc2009 (Kenny et al., 2004), and for the
4 phage tail protein 5 (Nakagawa et al., 1985). Moreover, we have
ecently demonstrated a muralytic activity of S. aureus phage P68
irion protein 17, which has a bipartite structure comprising the
uralytic activity in the N-terminal part, whereas the C-terminal
art encompasses the cell wall binding domain (Takácˇ and Bläsi,
005).
The human pathogen S. aureus is a cause of severe infections
n immuno-compromised individuals and a source of nosocomial
nfections. The widespread appearance of drug resistant strains of
. aureus especially to methicillin and vancomycin is a major issue
n combating this pathogen (Assadullah et al., 2003). The S. aureus
hage P68 endolysin (Lys16) was shown to exhibit muralytic activ-
ty against clinical isolates of S. aureus (Takácˇ et al., 2005). However,
he protein proved to be rather insoluble. To improve the solubil-
ty and to create a speciﬁc enzybiotic against S. aureus, here we
ombined the inferred N-terminal d-alanyl-glycyl endopeptidase
omain of P68 Lys16 with the C-terminal binding domain of P68
rotein 17. The chimeric P16-17 enzybiotic displayed antimicrobial
ctivity towards S. aureus, and a combination treatment with P16-
7 and sub-inhibitory concentrations of the antibiotics gentamicin
howed that the P16-17 can be used to reduce the effective dose.
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Table 1
Strains and plasmids used in the study.
Genotype/relevant features Source/reference
Bacterial strains
E. coli XL-1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44
relA1 lac [F’ proAB lacIqZM15 Tn10 (Tetr)]
Stratagene, USA
E. coli B F− ompT gal hsdSB New England Biolabs, USA
S. aureus 68 Host strain for phage P68 Vybiral et al. (2003)
S. aureus AS145 mecfemAB::tetK Stranden et al. (1997)
S. aureus RN4420 tagO Gründling and Schneewind (2006)
S. aureus strains P1, P2, P12, P16 and P17 Clinical strains Lab. collection
B. subtilis Lab. collection
Plasmids
pQE30 E. coli expression vector, lacUV5 promoter
Ampr
Qiagen, Germany
pUCLYS16 pUC18::793bp XbaI–XhoI fragment from
pDLYS16
Takácˇ et al. (2005)
pMUH17 pET16b::gene 17 of P68 Takácˇ and Bläsi (2005)
pDAGE1 pQE30::423bp PCR product containing the
5′-end of P16 gene under control of the lacUV5
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. Materials and methods
.1. Bacterial strains, plasmids and growth conditions
Bacterial strains and plasmids used in this study are listed
n Table 1. The S. aureus strains were cultivated in BHI broth
Merck) at 37 ◦C. E. coli and B. subtilis strains were cultivated in
uria-Bertani medium (LB) at 37 ◦C. When appropriate, ampicillin
100gml−1), tetracycline (10gml−1), gentamicin (40gml−1)
r streptomycin (40gml−1) was added. Where indicated, iso-
ropyl -d-1-thiogalactopyranoside (IPTG) was added to a ﬁnal
oncentration of 1mM.
.2. Construction of plasmids
To construct a plasmid encoding the chimeric protein P16-17,
445bp fragment comprising 423bp of the 5′-end of phage P68
ene 16 (pUCLYS16, Table 1) was ampliﬁed using primers FP1a and
P2a (Table 3; Supplementary material). The PCR fragment was
nserted into the BamHI/KpnI site of the expression vector pQE30
Table 1), creating plasmid pDAGE1. The PCR ampliﬁcation of gene
7 using plasmid pMUH17 (Table 1) with the primers FP12b and
P2b (Table 3; Supplementarymaterial) generated a DNA fragment
f 95bp comprising the 3′-terminal 75bp of gene 17. This fragment
as inserted into plasmid pDAGE1 cleaved with KpnI and HindIII,
r
p
ﬁ
c
p
ig. 1. (A) Synthesis of the recombinant P16-17 in E. coli XL-1 Blue (pHYBR1). Following I
nd subjected to sonication. After centrifugation at 28,000× g, equal amounts of protei
olyacrylamide gel. The gel was stained with Coomassie blue G250. (B) Puriﬁcation of
ontaining P16-17 were resolved on a 12% SDS polyacrylamide gel, which was then subjec
f P16-17 is indicated by an arrow.′-end of lys16 fused to
ene 17 under control of
This work
esulting in plasmid pHYBR1 (Table 1). Transcription of the P16-17
rotein gene in pHYBR1 is driven by the lacUV5 promoter.
.3. Puriﬁcation of P16-17
E. coli XL-1 Blue bearing plasmid pHYBR1 was grown to an
D600 of 0.3. Then IPTGwas added and incubationwas continued at
7 ◦C for 4h. The cells were collected by centrifugation at 5000× g
or 10min. As the synthesized P16-17 protein was insoluble
Fig. 1A) and accumulated in inclusion bodies (not shown), the cell
ellet was resuspended in 20ml denaturing lysis buffer (100mM
aH2PO4, 10mM Tris–Cl, 8M Urea, pH 8.0), and incubated at room
emperature for 1h followed by sonication. After sonication, the
ell lysatewas centrifuged at 28,000× g for 30min, the supernatant
as mixed with Ni-NTA agarose (Qiagen,), and incubated at room
emperature for 1h. The Ni-NTA bound P16-17 was eluted using
.0ml of buffer E (100mM NaH2PO4, 10mM Tris–Cl, 8M Urea, pH
.5). The eluate containing P16-17 was inactive as judged by zymo-
ramassays (not shown). Therefore, theP16-17 fractioneluted from
he Ni-NTA column was subjected to size exclusion chromatog-
aphy (Biogel A-15m, Bio-Rad) with the reasoning that denatured
roteinmay refold after removal of urea by passage through this gel
ltration column (Batas and Chaudhuri, 1996). Prior to loading, the
olumn (bed volume: 10ml) was equilibrated with 25mM Tris–Cl,
H 7.5. The proteins were eluted with 1.0ml of equilibration buffer.
PTG induction of gene 16-17 in E. coli XL-1 Blue (pHYBR1) the cells were harvested
n from the pellet (lane 1) and supernatant (lane 2) were resolved on a 12% SDS
P16-17 by size exclusion chromatography. Lane 1-4, equal amounts of fractions
ted to silver staining. The position of marker proteins is shown on the left and that
120 S. Manoharadas et al. / Journal of Biotechnology 139 (2009) 118–123
Fig. 2. BLAST analysis (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi?RID=4WN 45HN3015&mode=all) of the Lys16 domains and prediction of the 3-dimensional
structure of Lys16 and P16-17. (A) The location of the predicted CHAP and SH3 5 domains (Lu et al., 2006) within the Lys16 sequence is shown on top. A schematic depic-
tion of the P16-17 chimeric endolysin, comprising the N-terminal 141 aa of Lys16 and the C-terminal most 25 aa of P17 and the alignments of Lys16 with the consensus
CHAP and SH3 5 domains are shown below. Conserved residues are marked by stars. (B) The 3-D structure of Lys16 was predicted using the LOOPP program available at
http://cbsuapps.tc.cornell.edu/index.aspx. The C-terminal end of the 141 aa fragment containing the predicted DAGE domain of Lys16 is indicated by an arrow. (C) Predicted
3-D structure of P16-17 (http://cbsuapps.tc.cornell.edu/index.aspx). The arrow denotes the junction between the Lys16 141 N-terminal aa and the C-terminal 25 aa of P17 in
the hybrid protein.
f Biotechnology 139 (2009) 118–123 121
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Fig. 3. P16-17 displays muralytic and cell wall binding activity. (A) The protein frac-
tions were resolved on a 12% SDS polyacrylamide gel in the absence (lane 1 and 2)
or in the presence of autoclaved S. aureus B68 (lanes 3, 4 and 5) murein, respectively.
Lanes 1 and 2, electrophoretic pattern of protein fractions containing the enriched
Lys16141 fragment and the enriched P16-17 protein, respectively. Lanes 3–5, zymo-
gram assays with protein fractions, wherein P16-17 was absent (lane 3), containing
Lys16141 (lane 4) and enriched P16-17 (lane 5), respectively. The position of marker
proteins is indicated on the left. (B) Binding of P16-17 to the cell surface of S. aureus
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s judged by SDS-PAGE and silver staining P16-17 was 95% pure.
he protein was soluble and no precipitation was observed (not
hown). The P16-17 fraction shown in Fig. 1B, lane 4 was used
or further experiments. The activity, yield and purity of the P16-
7preparation(s) in E. coli lysates and after the different puriﬁcation
teps is documented in Table 4 (Supplementary material).
.4. SDS-polyacrylamide gel electrophoresis and zymogram
ssays
SDS-polyacrylamide gel electrophoresis was performed as
escribed (Laemmli, 1970). The gels were either stained with
oomassie brilliant blue G250 or by using the silver staining kit
AGESilverTM (Fermentas). The zymogram assays were carried out
s described by Lepeuple et al. (1998). Brieﬂy, 0.2% autoclaved S.
ureus 68 cells were embedded in SDS-gels. After electrophoresis
f the protein samples, the gel was incubated for 30min in dis-
illed water at room temperature, and then transferred into buffer
ontaining 25mM Tris (pH 7.5) and 0.1% Triton X-100, followed by
urther incubation for 16h at 37 ◦C. The gelwas rinsedwith distilled
ater, stained with 0.1% methylene blue in 0.001% KOH for 2h at
oom temperature, followed by de-staining with distilled water.
eptidoglycan hydrolase activity was visualized as a clear zone on
ark blue background.
.5. Cell wall binding assay
Five hundred nanograms of the P16-17 fraction was added to
00l of an overnight culture of S. aureus. After incubation at 37 ◦C
or 30min the cells were spun down at 15,000× g. The pellet was
ashed with BHI media followed by centrifugation at 15,000× g.
nbound protein present in the supernatant was precipitated with
% TCA at 4 ◦C for 1h. S. aureus bound P16-17 present in the cell pel-
et andunbound P16-17 present in the TCAprecipitate derived from
he supernatant were detected by Western-blotting using poly-
lonal antibodies raised in rabbits againstwhole phage 68particles,
.e. against virion proteins like P17.
. Results and discussion
.1. Construction of the chimeric P16-17 protein
Initially, we attempted to purify phage 68 Lys16 with the aim to
est its antimicrobial efﬁcacy towards clinical isolates of S. aureus.
owever, these experiments were unsuccessful owing to the poor
olubility of the protein (not shown). The N-terminal 112 amino
cids of phage 68 Lys16 are 50% homologous to the d-alanyl-
lycyl endopeptidase (DAGE) domain of the phage Twort endolysin
Loessner et al., 1998), and a BLAST analysis conﬁrmed the presence
f a CHAP domain (Fig. 2A), a typical signature found in enzymes
ithN-muramoyl-l-alanine amidase andd-alanyl-glycyl endopep-
idase activity (Bateman and Rawlings, 2003). The BLAST analysis
a
S
i
s
t
able 2
ntimicrobial activity of P16-17 in combination with gentamicin towards clinical S. aureu
. aureus Control (% reduction
in viability)
P16-17-f (% reduction
in viability)
Gent
in via
1 0 25±5 13 ±
2 0 33±2 17 ±
12 0 0 9 ±
16 0 32±3 17 ±
17 0 36±1 13 ±
he antimicrobial activity of 10gml−1of the protein fraction enriched for P16-17 (P16
16-17-f and 40ngml−1 gentamicin towards clinical S. aureus strains was tested by expos
ontrol protein fraction, wherein P16-17 was absent. The CFU and % survival (average of
inding (+) or lack of binding (−) of protein 17 to the respective S. aureus strains was detetrain68was revealedbymeansof immunodetectionusingantibodies raisedagainst
68 phage particles (see Section 2). Only the relevant part of the gels/Western-blot
s shown. Lane 1, P16-17 was found in the cell pellet (P), i.e. the protein associated
ith the cell surface; Lane 2, supernatant fraction (S).
urther suggested the presence of a cell wall binding domain at
he C-terminus of Lys16 that is homologues to the bacterial SH3 5
omain (Fig. 2A). The Learning, Observing and Outputting Protein
atterns (LOOPPs) program of the computational biology ser-
ice unit, Cornell University (http://cbsuapps.tc.cornell.edu/index.
spx) was used to assess the structure of the Lys16 protein. The
redicted structure of Lys16 revealed similarity with the crys-
al structure of the modular pneumococcal phage CPl-1 lysozyme
Hermoso et al., 2003) and with the endolysin of Listeria monocyto-
enes phage PSA (Korndörfer et al., 2006). The putative N-terminal
atalytic domain and C-terminal cell wall binding domain in Lys16
ere predicted to be separated by a linker sequence, which is like-
ise present in the endolysins of the phages CPl-1 and PSA (Fig. 2B).
First, we constructed several C-terminally truncated Lys16 pro-
eins to narrow down the catalytic domain (not shown). In agree-
ent with the sequence conservation of the N-terminus of Lys16
nd with the bioinformatic predictions, the shortest Lys16 variant,
ncompassing the N-terminal 141 aa (P16-141) exerted muralytic
ctivity towards S. aureus 68murein in zymograms (Fig. 3A, lane 4).
imilar to the entire Lys16 protein, P16-141 showed a poor solubil-
ty (not shown).With the rationale to construct a soluble enzybiotic
peciﬁc for S. aureus, next we determined the minimal sequence of
he cellwall targetingdomainof phage68protein 17. The functional
s strains.
am. (% reduction
bility)
P16-17-f+Gentam. (%
reduction in viability)
Cell wall binding of
protein 17
2 60 ± 6 +
5 62 ± 3 +
6 8 ± 3 −
4 59 ± 3 +
7 52 ± 8 +
-17-f), of 40ngml−1 gentamicin (Gentam.), and of a combination of 10gml−1of
ing 1×107 cfu of the respective strains to the antimicrobial agents or to 10gml−1
three experiments) was determined as described in the legend to Fig. 4. Cell wall
rmined by Takácˇ and Bläsi (2005).
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issection of Lys16 prompted us to construct a series of chimeric
16-17 proteins comprising the 141 N-terminal aa of Lys16 abutted
o different numbers of C-terminal aa of P17. The cell wall binding
apacity of the corresponding protein 16-17 variants were tested as
utlined in Section 2 for P16-17. In summary, these studies revealed
hat the C-terminal most 25 aa of P17 were sufﬁcient to target P16-
7 to the cell wall of S. aureus strain 68 (Fig. 3B, lane 1). This was
ather surprising as the cell wall targeting domains of endolysins
re generally larger in size (references in Loessner, 2005).
Recent attempts to identify the ligand required for binding of
17 to the cell surface made proteins, lipids and lipoteichoic acids
ess likely in serving this function. In a further search for a recep-
or of the P17 cell wall binding domain, we used the S. aureus
utant strains RN4420tagO (Gründling and Schneewind, 2006)
nd AS145 (Stranden et al., 1997), which are defective in the forma-
ionofpolyribitolwall teichoic acids and in thepentaglycine linkage
f the murein, respectively. The pentaglycine linkage is known to
e required for binding of lysostaphin (Gründling and Schneewind,
006). However, the P16-17 protein was shown to bind to the cell
all of either S. aureus mutant further excluding both structures as
eceptors (not shown).
.2. Antimicrobial activity of P16-17 towards S. aureusThe enriched P16-17 (purity∼95%) was soluble and displayed
uralytic activity towards S. aureus peptidoglycan in a zymogram
ssay (Fig. 3A, lane 5). The antimicrobial activity of P16-17 was
ested by exposing 1×107 cells of exponentially growing S. aureus
train 68 to different concentrations of the P16-17 containing sam-
o
t
s
s
t
ig. 4. Antimicrobial activity of protein P16-17. (A) The antimicrobial activity of P16-17 w
40min to 10gml−1 of cell lysate obtained from E. coli XL-1 Blue (pHYBR1) without indu
f the protein fraction containing P16-17 ( ). The antimicrobial activity of P16-17 towards
rowing cells to 10gml−1 of the protein fraction containing enriched P16-17. (B) 1×107
rotein fraction containing P16-17 () and (), S. aureus strain 68 was incubated with 10
f P16-17 synthesis and (), with 10gml−1 of the P16-17 fraction, which was boiled fo
40min (A) or at different times (B) after exposure to the protein fractions. Percent survi
xperiments were performed in triplicate. The error bars represent standard deviations.echnology 139 (2009) 118–123
le. A decline in colony forming units (cfu) was observed after
40min following addition of the P16-17 containing fraction at a
rotein concentration of 500ngml−1, 2 and 10gml−1, resulting
n the reduction of viable cells of S. aureus strain 68 to 32±3, 52±6
nd 95±3%, respectively (Fig. 4A). As anticipated, the addition of
0g P16-17 containing fraction did neither affect the viability of
. coli nor that of B. subtilis, underlining the speciﬁcity of P16-17
or S. aureus. Next, we monitored the loss of viability as a func-
ion of time upon addition of 10gml−1 of the P16-17 containing
raction to 1×107 cells of exponentially growing S. aureus 68. Fol-
owing addition, a reduction in the cfu to 48±4 and 6±2% was
bserved after 30 and 60min, respectively (Fig. 4B). As the addition
f 10gml−1 control extract (Fig. 4A and B) and heat inactivated
16-17 (Fig. 4B) did not affect the cell viability, we attributed the
bserved antimicrobial activity to P16-17.
.3. P16-17 reduces the effective dose of gentamicin
We have recently shown that infection of the Gram-negative P.
eruginosa with a ﬁlamentous phage reduced the effective dose of
everal antibiotics and that a combination treatment with phage
nd sub-inhibitory doses of the aminoglycoside antibiotic gentam-
cin, rescued mice from lethal P. aeruginosa K infections (Hagens et
l., 2006). The augmentation of the antimicrobial efﬁcacy of antibi-
tics by the ﬁlamentous phage can be most probably ascribed to
he formation of an aqueous channel in the cell envelope by a phage
peciﬁc protein (Russel, 1995). Similarly, cell wall-active antibiotics
uch as penicillin and vancomycinhave been shown to act synergis-
ically with membrane impermeable gentamicin, by increasing the
as tested by exposing 1×107 cells of exponentially growing S. aureus strain 68 for
ction of P16-17 synthesis (control) and 500pgml−1, 500ngml−1, 2 and 10gml−1
E. coli B ( ) and B. subtilis ( ) was tested by exposing 1×107 cfu of exponentially
cfu of exponentially growing S. aureus strain 68 was exposed to 10gml−1 of the
gml−1 of cell lysate obtained from E. coli XL-1 Blue(pHYBR1) without induction
r 5min. The cfu of the respective cultures were determined by serial plating after
val denotes the reduction in plating efﬁciency when compared to the control. The
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enetrationof the latter into thecell (Cottagnoudetal., 2003). These
tudies prompted us to testwhether perturbation of the cellwall by
16-17would likewise increase the sensitivity of theGram-positive
. aureus towards genetamicin. The minimal inhibitory concentra-
ions of gentamicin for the clinical S. aureus isolates P1, P2, P12, P16
ndP17were determinedwith 1gml−1 (not shown). For instance,
reduction in viability of 32±3 and 17±4% was observed when S.
ureus strain P16 (1×107 cfu) was treated with 10gml−1 of the
16-17 containing fraction or the sub-inhibitory concentration of
entamicin of 40ngml−1 (Table 2). However, the concomitant addi-
ion of 10gml−1 of the P16-17 containing fraction and 40ngml−1
f gentamicin resulted in a further reduction in viability of 59±3%
Table 2). Comparable results were obtained with the clinical S.
ureus isolates P1, P2 and P17. The clinical S. aureus strain P12 to
hich phage 68 protein 17 failed to bind (Takácˇ and Bläsi, 2005)
erved as a control. As anticipated, P16-17 did not affect the viabil-
ty and the synergistic effect of a combination treatment was not
bserved with this strain (Table 2).
We interpret this as showing that P16-17 causes mem-
rane damage, which increases the intracellular penetration of
entamicin. In this way, P16-17 seems be useful to increase the
ptake of aminoglycosides with a low membrane permeability, as
ell as to counteract resistance mechanisms affecting the cellu-
ar import of these antibiotics. P16-17 was less effective on the
linical S. aureus strains when compared to strain 68 (Table 2 and
ig. 4). Among other possibilities, one variable accounting for this
ould be the amino-acid composition of the peptidoglycan cross-
ridges that can vary in different S. aureus strains (De Jonge et al.,
993). Nonetheless, these initial experiments hold promise that the
oncomitant use of an enzybiotic and an antibiotic can reduce the
ffective dose of the latter, which seems to be especially desirable
or those antibioticswhich can exert severe side effects during high
ose treatment, such as gentamicin (Wersäll et al., 1969; Forge and
chacht, 2000).
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7.2. Direct interaction between ribosomal proteins S1 and S2 
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Abstract 
In recent years, the structure of the prokaryotic ribosome has been solved at atomic 
resolution. However, the binding site of the largest and essential ribosomal protein S1 of 
the 30S subunit is still questionable. There is biochemical evidence for interaction 
between proteins S1 and S2 and recent studies revealed the requirement of protein S2 
for assembly of S1 to the ribosome. Nevertheless, a direct interaction between these 
proteins has never been shown. Here, we scrutinized this protein-protein interaction 
employing a yeast-two hybrid system. The results presented indicate a direct S1-S2 
interaction. Precisely, the first N-terminal domain of protein S1 (S1106), encompassing 
106 amino acids was shown to interact with the α2 domain of protein S2, which was 
suggested to localize in close proximity to protein S1 on the ribosome. In addition, a 
random mutagenesis study of protein S1106 revealed specific amino acids involved in 
binding to protein S2 pointing towards the interaction surface on S1. Furthermore, we 
were also able to show that over-production of S1106 affects bacterial growth by binding 
to the 70S ribosomes and thereby blocking the assembly of endogenous protein S1. 
Taken together, these results indicate the direct S1-S2 interaction, which is essential for 
translation in Gram-negative bacteria. Moreover, these results support the notion that 
this interaction surface could serve as a potential target for the design of novel 
antimicrobial compounds acting semi-selectively against Gram-negative pathogens.  
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Introduction 
Ribosomal protein S1 is the largest ribosomal protein in E. coli with a molecular weight of 61 
kDa. It is one of the last proteins which associate with the 30S subunit during ribosome 
biogenesis (Culver, 2003) and binding of protein S1 to the 30S subunit is weak and reversible 
(Subramanian, 1983). Sequence analysis of protein S1 reveals the presence of six repeating 
motifs, the ‘so-called’ S1 domains (Fig. 1; Bycroft et al., 1997). The two N-terminal domains 
are involved in binding to the ribosome (N1-N2; McGinness and Sauer, 2004; Subramanian et 
al., 1981). Domains R1-R3 bind ssRNA and RNA pseudoknots (Fig. 1; Boni et al., 1991; 
Subramanian, 1983; Aliprandi et al., 2008). The distal domain R4 has been suggested to be 
important for autogenous regulation of rpsA (Boni et al., 2001). Protein S1 is essential for 
translation initiation of canonical mRNAs and especially for the translation of highly 
structured mRNAs (Szer et al., 1975; van Dieijen et al., 1976). It interacts with a pyrimidine-
rich region upstream of the SD-sequence and in addition, it has been shown to unwind RNA 
secondary structures (Bear et al., 1976; Thomas et al., 1978; Rajkowitsch and Schroeder, 
2007), thereby facilitating the positioning of the 30S subunit in close proximity to the 
translational start site (de Smit and van Duin, 1994). However, S1 is dispensible for 
translation of leaderless mRNAs (Tedin et al., 1997; Moll et al., 2002a). In addition, a recent 
study suggests the formation of 61S ribosomes in the presence of the antibiotic kasugamycin 
in vivo (Kaberdina et al., 2009). These 61S particles are devoid of several ribosomal proteins 
of the small subunit including the functionally important proteins S1 and S2. However, these 
ribosomal particles are proficient in translation of leaderless mRNAs (Kaberdina et al., 2009).  
Protein S1 is the only 30S subunit protein which binds to the ribosome by means of 
protein-protein interactions (Boni et al., 1982). Cross linking experiments suggest a direct 
interaction between proteins S1 and S2 (Laughrea and Moore, 1978; Bollen et al., 1979). In 
addition, cryo-electron microscopy indicates that the N-terminal domain of S1 penetrates into 
the head of the 30S subunit, whereas the C-terminal part is exposed to the solvent side, facing 
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protein S2 (Sengupta et al., 2001). Studies performed by Moll et al. (2002) revealed that 
protein S2 is required for the binding of protein S1 to the ribosome. These results support the 
possible interaction between proteins S1 and S2.  
In this study, we verified the direct interaction between ribosomal proteins S1 and S2. 
Our data revealed that the N-terminal domain of protein S1 (referred here as S1106) and the α2 
domain of protein S2 is essential for this interaction. In addition, mutational analysis of S1106 
indicates the amino acid residues important for the interaction with the α2 domain of protein 
S2.  
Materials and Methods 
Bacterial strains, plasmids and growth conditions 
Bacterial strains and plasmids used in this study are listed in Table 1.  E. coli strains were 
cultivated in Luria-Bertani medium (Miller, 1972) at 37oC. When appropriate, ampicillin (100 
µg ml-1), was added. Where indicated, isopropyl β-D-1-thiogalactopyranoside (IPTG) was 
added to a final concentration of 50 µm or 1 mM.  Yeast strain (HF7c) was grown in YPD 
medium or in synthetic dropout medium lacking Leu, Trp or both (Clontech, US). In order to 
prevent false positive results during the restoration of His auxotrophy, 3-amino-1,2,4-triazole 
(Sigma, US) was used to a final concentration of 5 mM when mentioned.  
 
Construction of plasmids 
To purify the truncated variant of protein S1, genes encoding the ribosomal protein S1 and 
truncated variant of protein S1 (S1106), were amplified by primers FPS1 and RPS1, FPS1 and 
RPS1106 (Table 2) thereby yielding a 1671 and 318 bp fragment, respectively from the E. 
coli (MC4100) bacterial chromosome. The amplified fragments were cloned as NdeI/XhoI 
into pET22b (+) vector (Novagen) creating the plasmids pS1 and pS1106 (Table 1), 
respectively. The transcription of the S1 and S1106 protein gene in pS1 and pS1106 is 
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controlled by a T7-promoter. Similarly, the gene encoding the mutant S1106 protein was 
amplified by primers FPS1 and RPS1106 using pGBTS1106MUT (Table 1) as template. The 
PCR amplified 318 bp fragment was cloned into pET22b plasmid as NdeI/XhoI, creating the 
plasmid pPETMUTS1106. 
For elucidating protein-protein interactions in vivo, the yeast two hybrid system was 
employed. Two plasmids, pGBT9 (harboring the Gal4 DNA-binding domain, DBD) and 
pGAD424 (harboring the Gal4 activation domain, AD) were used for the studies. Genes 
encoding the ribosomal proteins S1 and S2 were amplified using the primers 
FPY2HS1/RPY2HS1 and FPY2HS2/RPY2HS2 (Table 2), respectively. To obtain the Gal4 
DBD- and AD-protein fusion genes, the PCR amplified products (1671 bp and 750 bp, 
respectively) were cloned into the EcoRI/BamHI site of the plasmid pGBT9 and pGAD424, 
thereby creating the plasmids pGBTS1 and pGADS2, respectively (Table 1). Similarly, the 
gene encoding S1106 and the mutant S1106 were amplified by the primers FPY2HS1 and 
RPY2HS1106. The amplified product of size 318 bp was cloned into pGBT9 plasmid as 
EcoRI/BamHI creating the plasmid pGBTS1106 and pGBTS1106MUT (Table 1). The gene 
encoding a truncated variant of protein S1 harboring both N-terminal domains (S1194) was 
amplified by primers FPY2HS1 and RPY2HS1194 yielding a 582 bp fragment. This 
amplified PCR product was cloned as EcoRI/BamHI into the plasmid pGBT9, thus creating 
the plasmid pGBTS1194 (Table 1). The gene encoding the α2 domain of protein S2 was 
cloned into pGAD424 vector following amplification using primers FPY2HS2 and 
RPY2HS2helix (Table 2). The 150 bp PCR amplified fragment was cloned as EcoRI/BamHI, 
creating the plasmid pGADS2helix (Table 1). 
 
Random mutagenesis using error prone PCR 
In order to introduce mutations into gene encoding for protein S1106, plasmid pS1106 was 
amplified with primers FPS1 and RPS1106. The error prone PCR has been performed under 
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the following conditions: 7 mM MgCl2, 50 mM KCl, 20 mM Tris (pH 8.4), 0.5 mM MnCl2, 1 
mM dTTP, 1 mM dCTP, 0.2 mM dGTP, 0.2 mM dATP. The amplified 318 bp fragment was 
cloned into corresponding plasmid as described above. 
 
Analysis of protein interactions using a yeast two hybrid system  
The yeast two hybrid system experiments were performed according to manufacturers 
description (Clontech, US). The β-galactosidase assays from yeast cells were performed as 
described (Guarente, 1983; Miller, 1972).  Three independent assays were performed for each 
mutant. 
 
Purification of proteins S1106 and mutant S1106. 
E. coli TUNER bearing plasmid pS1106 and pPETMUTS1106 were grown to an OD600 of 0.8. 
Then 1.0 mM IPTG was added and incubation was continued at 37 °C for 2 h. The cells were 
harvested by centrifugation at 6000 × g for 10 min. The pellet was resuspended in 20 ml lysis 
buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 100 mg ml-1 lysozyme, 24 mg 
ml-1 RNase A, pH 8.0), followed by freezing and thawing in liquid nitrogen and sonication.  
Upon centrifugation at 30,000 × g for 15 min, the supernatant was mixed with Ni-NTA 
agarose (Qiagen, US), and incubated at 4oC for 1 h. The Ni-NTA bound S1106 and MUTS1106 
were washed with buffer C (1.5 M NaCl, 50 mM NaH2PO4, 0.1 % Triton-X 100, 20 mM 
Imidazole, pH 8.0) and eluted using 2.0 ml of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 
250 mM Imidazole, pH 8.0). The eluates containing the purified proteins were dialyzed 
against buffer 1x VD buffer (10 mM Tris-Cl, 10 mM MgOAc, 60 mM NH4Cl, 3 mM β-
Mercapto-EtOH, 100 mM PMSF, 10 % glycerol, pH 7.5).  
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Purification of crude ribosomes upon overexpression of the truncated rpsA gene 
The E. coli strain TUNER harboring plasmid pS1106 was grown in LB to an OD600 of 0.2. At 
time points 0, 20, 40, 60, and 90 min upon addition of 0.5 mM IPTG, the cells were harvested 
by centrifugation at 6000 x g for 10 min followed by the resuspension of the pellet in VD 
buffer (10 mM Tris-Cl, 10 mM MgOAc, 60 mM NH4Cl, 3 mM β-Mercapto-EtOH, 100 mM 
PMSF, 100 mM Benzamidine, Dnase I, 100 mM DTT, pH 7.5). The cells were disrupted by 
sonocation and upon centrifugation at 12000 x g for 10 min the supernatant was withdrawn 
and re-centrifuged at 15000 x g for 30 min. The supernatant was layered onto 1.1 M sucrose 
cushion made up in VD buffer. Upon centrifugation at 30000 x g for 60 min the pellet 
containing crude ribosomes was resuspended in VD buffer and stored at -80oC. 
 
Purification of 30S(-S1) 
The 30S ribosomal subunits were prepared essentially as described by Spedding (Spedding, 
1990). Protein S1-depleted 30S ribosomes were prepared by affinity chromatography using 
poly(U)-Sepharose 4B (Pharmacia) (Suryanarayana and Subramanian, 1983).  
 
 In vitro binding of S1106 and S1106Mut to 30S(-S1)  ribosomes  
The purified S1106 and S1106Mut (100 pm) were incubated with 30S(-S1) (50 pm) ribosomes at 
37oC for 20 min followed by loading onto a sucrose gradient (10-30%) made up in VD buffer. 
Upon centrifugation for 5 h at 45000 x g, the gradients were fractionated using an ISCO 
UV/VIS detector (ISCO, US). The fractions containing 30S ribosomes were treated with 5% 
TCA at 4oC and precipitated proteins were separated on a 12% SDS-PAGE as described by 
Laemmli (1970). The S1 variants bound to the 30S ribosomes were detected by western blot 
analysis. 
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Western blot analysis  
Upon separation of the ribosomal proteins by SDS-PAGE, the proteins were transferred to a 
nitrocellulose membrane (Whatman, Germany) by employing a semi-dry blotting apparatus. 
The nitrocellulose bound proteins were detected by either monoclonal anti-bodies specific for 
His-tag raised in rabbits (Qiagen) or with polyclonal antibodies specific against ribosomal 
proteins derived from goat. 
Results  
Overexpression of S1106 affects growth of E. coli  
The over production of the N-terminal domain of protein S1 comprising the first two domains 
(194 aa) is toxic for E. coli (McGinness and Sauer, 2004). It is suggested that the fragment 
binds to the ribosome and displaces endogenous protein S1, which leads to inhibition of 
protein synthesis and cessation of cell growth. Here, we aimed to determine whether the very 
N-terminal domain of S1 consisting of 106 amino acids from the N-terminus inhibit cell 
growth. Therefore, E. coli strain Tuner harbouring the plasmid pS106, which codes for the 
truncated variant S1106, was over produced by addition of IPTG. As shown in Fig. 2A, the 
over production of S1106 affects the growth of E. coli comparable to overexpression of the 
truncated rpsA194 gene encoding protein S1194. The growth of both, S1106 and S1194 
overproducing strains, ceased 80 min upon induction. As control, overexpression of the rpsA 
gene encoding the full length protein S1 was included, which resulted in a slight reduction of 
cell growth. In order to confirm the binding of S1106 to the ribosome, concomitantly samples 
were withdrawn from the respective culture at specific time points following induction of 
S1106 synthesis and crude ribosomes were purified. To determine whether S1106 binds to the 
70S ribosomes the ribosomal proteins were precipitated using TCA and subjected to SDS-
PAGE analysis as described in Materials and Methods. Protein S1106 was identified by 
Western blot analysis using antibodies specific for the histidine tag (Fig 2B). As loading 
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control protein S2 was identified using S2 specific antibodies (Fig. 2B, upper panel). As 
shown in Fig. 2B, we were able to verify the binding of protein S1106 to the ribosome already 
20 min upon induction (Fig. 2B, lane 3). Furthermore, the amount of protein S1106 increased 
during prolongued induction compared to the amount of protein S2 (lanes 4-6).   
 
Interaction of S1106 with S2 
Biochemical studies suggested the close proximity of interaction between proteins S1 and S2 
on the ribosome (Sengupta et al., 2001). Furthermore, the association of protein S1 to the 30S 
subunit is dependent on protein S2 (Moll et al., 2002; Laughrea and Moore, 1978; Bollen et 
al., 1979). As S1106 has been shown to bind to the 70S ribosome, the next aim was to 
elucidate, whether the first domain of protein S1 is responsible for the interaction with protein 
S2. To monitor the protein-protein interaction, we employed a yeast two hybrid approach as 
described in materials and methods, where interaction of the proteins resulted in the synthesis 
of β-galactosidase. As shown in Fig. 3 the β-galactosidase activity given in Miller units (MU) 
increased when the plasmids coding for the Gal4DBD-S1106 fusion protein and the Gal4AD-
S2 fusion protein were used, compared to the assay when the whole length S1 and S1194 (two 
N-terminal domain of S1: 194 aa) was used. These data indicate the direct interaction between 
S1106 and S2. These results are in line with the previous observation that ribosomes lacking S2 
in turn lacks S1 (Moll et al., 2002). It is therefore likely that the binding of S1 to the 30S 
subunit requires direct interaction of its N-terminal domain with protein S2.  
 
Identification of amino acids involved in S1/S2 interaction  
To determine which amino acids of S1106 are involved in interaction with protein S2, next a 
random mutagenesis study was performed. Employing error prone PCR random mutations 
were introduced into the gene encoding protein S1106 and the mutant proteins were tested for 
their ability to interact with protein S2 using the yeast two hybrid approach. Upon 
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transformation of the plasmid library harboring the genes encoding mutant S1106 into the yeast 
strain harboring plasmid pGAD424S2, we selected transformants yielding reduced or 
increased β-galactoside activities compared to the wild type S1106, indicating an affected 
affinity between the S1106mut and S2. The subsequent sequencing of the genes coding for the 
mutant S1106 proteins were performed (Agowa, Germany). As shown in Fig. 4A, three 
mutants of protein S1106, S1106Mut#13, S1106Mut#18, and S1106Mut #19 yielded no significant MU 
read out, suggesting that they are not able to interact with protein S2. However, sequence 
analysis revealed the presence of an internal stop codon in #13 and #18, which explains the 
lack of interaction with protein S2 (Fig. 4A). However, S1106Mut #19 harbours a Val→Ile 
mutation at position 35 (Fig. 4A). In addition, increased β-galactoside activity yielded by the 
mutant S1106Mut#2, which harbours two point mutations at position 40 (Ala→Ser) and position 
43 (Lys→Ile), indicated a stronger interaction with protein S2 as compared to the wild type 
S1106. As shown in Fig. 4B these residues are conserved throughout Gram-negative bacteria. 
Taken together, these results indicate the importance of the region covering aa 34-45 for 
interaction with protein S2. In silico analysis of the N-terminal domain of protein S1 suggests 
that this motif represents a hinge between two a-helices, as depicted in Fig. 4B. Therefore, 
changes in the amino acid sequence might lead to a structural rearrangement which might 
affect protein-protein interaction.   
  To further validate the binding of proteins S1106 and S1106Mut#2 to 30S(-S1) ribosomes 
in vitro, both proteins were purified using affinity chromatography as described in Materials 
and Methods. Upon incubation of the S1-depleted 30S subunits with the truncated S1-variants, 
the mixture was layered onto a sucrose gradient and ribosomal subunits were separated from 
free S1106 proteins by centrifugation. The fractions containing the 30S subunits were tested for 
the presence of the respective S1 variants by Western blot analysis. As shown in Fig. 4C, 
although the 30S subunits were not completely depleted for S1, both variants of S1, S1106 and 
S1106Mut#2, are present in the 30S fraction, indicating their interaction with the ribosome. 
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S1106 interacts with the α2 domain of S2  
The α-helix domain of protein S2 was suggested to be located in the close proximity to S1 
(Sengupta et al., 2001; Fig. 5A). This helix-loop-helix motif spans the region from amino acid 
104 to amino acid 150 of protein S2 (Fig. 5B). We therefore anticipated that this protruding 
domain of protein S2 might be involved in interaction with S1. To validate this possiblity, the 
interaction with protein S1106 was analyzed using the yeast two hybrid system. Compared to 
the β-galactosidase activity determined for the interaction between S1106 and full length 
protein S2 (Fig. 5C, lane 3), the results show a comparable interaction between the α2 domain 
of protein S2 and S1106 (Fig. 5C, lane 6).  
 
Discussion 
Direct interaction between protein S1 and S2 
Protein S1 is one of the most important proteins of the 30S subunit and is involved in 
translation initiation, elongation and trans-translation of canonical mRNAs in Gram-negative 
bacteria (Tzareva et al, 1994; Potapov and Subramanian, 1992). It has been shown that over 
production of the two N-terminal domains of S1 (S1194; McGinness and Sauer, 2004) was 
toxic for the cells. Therefore, these domains were termed the “ribosome binding domain” of 
S1. Here, we were able to show that expression of the rpsA106 gene coding for the first N-
terminal domain of S1 (S1106) is sufficient to inhibit cell growth (Fig. 2A). Moreover, we 
were able to verify binding of S1106 to crude ribosomes upon overexpression (Fig. 2B). 
Therefore, it could be assumed that the toxicity of the synthesis of S1106 could be attributed to 
the accommodation of the truncated S1106 within the binding pocket of whole length S1 on the 
30S subunit. Consequently, this binding would inhibit assembly of endogenous protein S1 to 
the ribosome. Taken together, our data suggest that the N-terminal domain of S1 (S1106) is 
sufficient for the interaction with the ribosome. Several studies indicate the close proximity of 
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S1 to the ribosomal protein S2 (Sengupta et al., 2001), and recent work by Moll et al. (2002) 
support the hypothesis, that protein S2 is required for assembly of S1 on the ribosome. Here, 
we were able to support this notion by employing a yeast two hybrid analysis, which reveals 
the interaction between ribosomal proteins S1 and S2. Furthermore, these results demonstrate 
that the N-terminal domain of S1 (S1106) is sufficient for efficient binding to S2.  
In addition, employing a random mutation analysis we identified amino acids and domains of 
S1106, which might contribute to the interaction with protein S2. Significantly, two point 
mutations in S1106 located at amino acid position 40 and 43, which are conserved in Proteo-
bacteria, increased the affinity to protein S2. Precisely, the non-polar alanine residue at 
position 40 was replaced to a polar serine residue. The second mutation comprised the change 
of the polar lysine residue at position 43 to the non-polar isoleucine (Fig. 4B). Interestingly, in 
the low “GC” group of Gram-positive bacteria, which do not require binding of S1 to the 
ribosome for translation, these amino acids are not conserved. Furthermore, since these 
mutations are located between two predicted α-helices in protein S1106, these amino acids 
could be important for the positioning of these helices, which might provide the interaction 
surface for protein S2.  
In addition to the mutational analysis on protein S1106, another aim of the study was 
the identification of a possible interaction domain on protein S2. The structural analysis of 
protein S2 reveals that it is a slightly elongated protein with a two-domain organization 
(Georgalis et al., 1981; Wittmann et al., 1980) The elongated α2 domain of protein S2 is 
located in close proximity to protein S1 on the ribosome (Sengupta et al., 2001), suggesting 
that it might serve as site of interaction for S1. Therefore, we tested whether the α2 domain, a 
helix-turn-helix motif situated between amino acids 104 and 150 of S2, is able to bind to 
protein S1. Using the yeast two hybrid system, we observed a significant interaction between 
the α2 domain and protein S1 as well as S1106 (Fig. 5C). This observation leads to the 
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conclusion that interaction between proteins S1 and S2 occurs between the N-terminal S1-
domain and the S2-α2 domain.   
 
The interaction surface between proteins S1 and S2: A possible target for novel 
antimicrobials  
Antibiotics are low molecular weight compounds produced by microorganisms that kill or 
inhibit the growth of other microorganisms at concentrations in the µM range. The majority of 
clinically relevant antibiotics target the ribosome. Precisely, numerous antibiotics bind to 
functionally important regions within the 16S rRNA in order to establish contact with the 
ribosome and block its function (Yonath, 2005). As a consequence, point mutations in the 16S 
rRNA gene exploited by ‘natural selection’ often confer bacterial resistance towards several 
antibiotics targeting the ribosome (Skinner et al., 1983). In addition, since these functionally 
imortant sites of the protein synthesis machinery are conserved within eukaryotes, bacteria 
and mitochondria, these drugs can have adverse side effects when used as clinical therapeutics. 
Thus, there is a need for alternative antimicrobials, which exhibit a higher specificity.  
Since specific protein-protein interactions are essential in most biological processes, 
disruption of highly bacterial specific protein-protein interactions by competitive molecules 
could represent potential tool to specifically inhibit growth of bacteria (Arkin and Wells, 
2004; Toogood, 2002). As mentioned above, S1 is an important protein bound to the 
ribosome by the help of protein S2. Since our results suggest that interaction between protein 
S1 and S2 plays a crucial role in the translation initiation in E. coli and as a S1 homologue is 
absent in the low GC-group of Gram-positive bacteria, it is conceivable that a compound with 
the potential to inhibit the assembly of S1 on the ribosome by interfering with S1/S2 
interaction could be a potential antimicrobial that specifically inhibits growth of Gram-
negative bacteria. Moreover, resistance towards drugs, which are based on an alteration of a 
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protein-protein interaction site, are more difficult to develop as point mutations in 16S rRNA, 
since most alterations would be detrimental for the cell.   
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Figure legends: 
FIG.1. Schematic depiction of the different domains of ribosomal protein S1. The N-
terminal repeats, required for binding to the ribosome (Giorginis and Subramanian, 1980) and 
the C-terminal RNA binding domains (Bycroft et al., 1997) are shown in grey and black, 
respectively.  Numbers shown above indicate amino acid positions. 
FIG. 2. Synthesis of S1106 causes cell death by binding to the ribosome. (A). Growth of E. 
coli cells synthesizing S1106. The cells carrying the corresponding plasmids (pS1, pS1106 and 
pET22b) harboring genes encoding for proteins S1, or S1106, respectively, were induced with 
50 µm IPTG. Growth was monitored by measuring the OD600. 80 min upon induction of the 
gene encoding S1106 and S1194, cessation of growth was observation. Overexpression of the 
rpsA gene encoding for the full length S1 protein only slightly affected cell growth (B). 
Binding of protein S1106 to the ribosome. Western blot analysis of the crude ribosome fraction 
reveals that 20’, 40’, 60’ and 90’ upon induction protein S1106 was bound to the ribosome. 
The amount of S1106 bound to the ribosome increase with time after induction of gene 
encoding S1106 (lanes 2-6) compared to protein S2, which served as internal control. Lane 1: 
purified 70S ribosomes.  
FIG. 3. Yeast two hybrid system indicating the interaction between S1 and its truncated 
variants with S2. The β-galactosidase activity given in Miller Units (MU) was used as 
reporter for the protein-protein interactions. Bars 1 and 2: controls lacking one interaction 
partner; bar 3: MU representing interaction between S1106 and S2; bar 4: Interaction between 
S1194 and S2; bar 5: Interaction between S1 and S2. Schematic representation of the protein 
domains of S1 and S2 used for the interaction studies in each experiment are indicated in blue 
(S1) and red (S2) below. The experiments were done in triplicates and error bars represent 
standard deviation. 
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FIG. 4. Yeast two hybrid system indicating interaction between S1106Mut with S2 (A) 
Interaction of S1106Mut towards S2 as detected by yeast two hybrid system. Bars 1 and 2: 
controls lacking one interaction partner; bar 3:  MU representing interaction between S1106 
and S2; bar 4: Interaction between S1106Mut#2 and S2; bars 5, 7 and 9: Interaction between 
S1106Mut#13, S1106Mut#18 and S1106Mut#19 with protein S2; bars 6 and 9: Interaction between 
S1106Mut#15 and S1106Mut#20 with protein S2. Schematic representation of the protein domains 
of S1 and S2 used for the interaction studies in each experiment are indicated in blue (S1) and 
red (S2) below. Error bars represent standard deviation. The mutated amino acids are shown 
in red below. (B) Alignment showing the site of mutation on protein S1106Mut#2 as compared 
to protein S1106 from different bacteria. Sequence conservation of protein S1 in various Gram-
negative bacteria is shown. (C) In vitro binding of S1106 and S1106Mut to 30S (-S1). Lane 1: 
The 30S control; lane 2: protein S1; lane 3: 30S ribosomal subunit depleted of protein S1; 
lane 4: purified protein S1106 used for in vitro binding studies; lane 5 and 6: 30S bound S1106 
and S1106Mut detected by western blot analysis. 
 FIG. 5. Yeast two hybrid system indicating interaction between α2 domain of S2 with 
S1 and S1106. (A) The encircled region shows the close proximity of α2 domain of protein S2 
to protein S1 (Sengupta et al., 2001). (B) The helix-turn-helix of α2 domain of protein S2 
from E. coli.  (C) The interaction between the α2 domain of S2 with whole length S1 and 
S1106 were validated by yeast two hybrid analyses. Bars 1 and 2: controls lacking one 
interaction partner; bar 3: MU representing interaction between S1106 and S2; bar 4: 
interaction between S1 and S2; bar 5: interaction between S1 and S2-α2 domain; bar 6: 
interaction between S1106 and S2-α2 domain. Schematic representation of the protein domains 
of S1 and S2 used for the interaction studies in each experiment are indicated in blue (S1) and 
red (S2) below. The experiments were done in triplicates and error bars represent standard 
deviation. 
 116
Table 1. Strains and plasmids 
                                                                          Genotype/                                                               Source 
                                                                           Relevant features             
     
      Strains 
   E. coli TUNER                      F– ompT hsdSB (rB– mB–) gal dcm lacY1                                       Novagen, US 
   E. coli XL1-blue                    recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1                        Stratagene, US 
                                                 lac [F' proAB lacIqZM15 Tn10 (Tetr) ]c    
                                                                                      
   Yeast HF7c                           MATa, ura3-52, his3-200, lys2-801, ade2-101, trp1-901,            Clontech, US                  
                                                leu2-3, 112, gal4-542, gal80-538, LYS 2::GAL1UAS- 
                                                GAL1TATA-HIS3, URA3::(GAL 17mers) 3-Cyc1TATA-lacZ 
 
   Plasmids 
    pET22b (+)                          5.4 kb E.coli expression vector, His-tag at C-terminal                  Novagen, US   
                                                   T7 promoter, Ampr , IPTG induction  
 
   pGBT9                                5.5 kb vector for yeast two hybrid system consisting                       Clontech, US    
                                               binding domain. +leu, Ampr 
 
   pGAD424                           6.6 kb vector for yeast two hybrid system consisting                       Clontech, US 
                                               activation domain. +trp, Ampr 
 
    pS1                                      pET22b ::  1671 bp PCR product containing the                            This work 
                                                 S1 gene under T7 promoter. 
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   PS1106                               pET22b ::  318 bp PCR product containing the                              This work 
                                                S1106 gene under T7 promoter. 
 
 pPETMUTS1106              pET22b ::  318 bp PCR product containing the                              This work 
                                               mutant S1106 gene under T7 promoter. 
 
 
  pGBTS1                              pGBT9 :: 1671 bp PCR product containing the                              This work 
                                                 S1 gene. 
 
pGBTS1106                          pGBT9 :: 318 bp PCR product containing the                                This work 
                                                 S1106 gene. 
 
pGBTS1194                          pGBT9 :: 582 bp PCR product containing the                                This work 
                                                 S1194 gene. 
 
pGBTMUTS1106                 pGBT9 :: 318 bp PCR product containing the                                This work 
                                                 mutant S1106 gene. 
 
pGADS2                              pGAD424 :: 750 bp PCR product containing the                             This work 
                                                 S2 gene. 
 
pGADS2helix                      pGAD424 :: 150 bp PCR product containing the                             This work 
                                                 S2 alpha helix gene. 
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Table 2. Primers used for PCR amplification 
  
        Oligos                                                                                    Sequence (5’-3’)    
 
 
      FPS1                                                         AATTCATATGATGACTGAATCTTTTGCTCA                                                         
 
      FPY2HS1                                                 AATTGGATCCGAATTCATGACTGAATCTTTTGCTCA 
 
      FPY2HS2                                                 AATTGGATCCGAATTCATGGCAACTGTTTCCA 
 
     RPS1                                                         AATTGGATCCCTGCAGTTACTCGCCTTTAGCTG 
 
     RPS1106                                                   AAGCGTCGACTAACTCGAGTTCAGCATCTTCG 
 
     RPY2HS1                                                 AATTGGATCCCTGCAGTTACTCGCCTTTAGCTG        
 
     RPY2HS1106                                           AATTGGATCCCTGCAGTTATTCAGCATCTTCGTAAG 
 
     RPY2HS1194                                           AATTGGATCCCTGCAGTTATTCCATGCCTTCC 
  
     RPY2HS2                                                 AATTGGATCCCTGCAGTTACTCAGCTTCTACGAAGC  
 
 
 Underline represents the restriction sites 
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